Executive Summary

In the current environment of interoperability among health care information systems, it has become increasingly important for immunization information systems (IIS) to control the quality of data in their systems. The growing number of health care providers who submit data via Health Level 7 (HL7) interfaces has created a need for IIS to evaluate data in new ways – before permitting the submission of data into their production systems. To build on the work already done in this area and reduce further duplication of effort among IIS, the American Immunization Registry Association (AIRA) initiated a project in 2016 to research, review, and make recommendations for onboarding processes and practices specific to data validation.

This guide was developed to provide practical guidance on data quality measures to implement in an IIS during the onboarding process. The audience includes IIS managers and other IIS staff members, Immunization Program managers, IIS and AIRA partners, and electronic health record (EHR) vendors. The guide builds on business rules developed in earlier documents such as the MIROW Best Practices Guides on Data Quality Assurance. It identifies and highlights proven practices used in the IIS community and gives IIS a resource for building or expanding their own onboarding data validation processes.

This guide was developed in expectation that each IIS program will adjust the implementation of the recommended business rules and practices to their own specific needs and unique implementation concerns. The recommendations and examples represent an attempt to balance ideal practices with pragmatic considerations of what is possible within the IIS.

Topics covered in the guide include:

- Source of data for the validation process
- Parameters for the test data load
- Accuracy and completeness measures with suggested thresholds
- Methodology approaches - aggregate data review and individual patient record review
- Roles of IIS, provider organization and electronic health record (EHR) staff
- Helpful hints for successful implementation
- Preparations to Go Live
- Short term data validation after Go Live
- Sample data quality reports from IIS
# Executive Summary

Table of Contents .................................................. a
Table and Figures ..................................................... b
Acknowledgments ....................................................... c

## Section 1: Introduction ........................................... 1
- Background ......................................................... 1
- Purpose ............................................................ 1
- Audience .......................................................... 2
- Methodology ........................................................ 2
- Scope of Work .................................................... 2
- Primary Resource Materials .................................... 3

## Section 2: Onboarding Steps .................................... 4
- Onboarding Overview ............................................. 4

## Section 3: Data Validation Process .............................. 6
- Source of Data for Validation Process ......................... 6
- Parameters for Data Set .......................................... 6
- Data Quality Components ....................................... 7
- Selecting Metrics and Thresholds .............................. 7
- Accuracy Measures ............................................... 7
- Completeness Measures ........................................ 12

## Section 4: Implementation Considerations/Approaches .... 17
- Methodology ........................................................ 17
- Aggregate data review .......................................... 17
- Individual Patient Record Review ............................. 18
- Roles ................................................................. 19
- Helpful Hints for Successful Implementation of Data
  Validation Processes ............................................. 20
- Other Issues ........................................................ 21

## Section 5: Preparations to Go Live ............................... 22
- Short Term Data Quality Review after Go Live ............ 22

## Section 6: Conclusion .............................................. 23

### Appendix A – Abbreviations & Terminology .................. 24
- Appendix A-1: Abbreviations .................................. 24
- Appendix A-2: Definitions of Terms .......................... 25
- Appendix A-3: Health Level 7 (HL7) Description ........... 26

### Appendix B – References ......................................... 27

### Appendix C – Onboarding Documents ......................... 29
- Appendix C-1: Sample of Onboarding Readiness Checklist for Provider Organizations ........................... 29
- Appendix C-2: Sample Onboarding Process Document .......................................................... 30
- Appendix C-3: Sample Go Live Checklist .................... 33

### Appendix D – Details on Data Checks from MIROW Guides 34
- Appendix D-1: Selected Data Checks table from MIROW Data Quality Guide ........................................ 34
- Appendix D-2: Provider Organization Profile Information ................................................. 35
- Appendix D-4: Minimum/Mandatory Dataset from BR 105, 2013 MIROW Guide ............................. 37

### Appendix E – Core Data Elements ............................... 38

### Appendix F – Sample Data Quality Reports ................... 39
- Appendix F-1. Reports from Massachusetts IIS ............ 39
- Appendix F-2. Report Cards from Wisconsin IIS .......... 41
- Appendix F-3. Reports from Colorado IIS .................. 44
- Appendix F-4. Reports from NYC Citywide
  Immunization Registry ............................................. 48
- Appendix F-5. Pre-HL7 Message Review Process
  Description – from Missouri ................................. 49
Figure 1. Onboarding Process Steps for HL7 Electronic Data Exchange .............................................. 5
Table 1. Business Rules for Accuracy Validation.................................................................................. 9
Table 2. Recommendations for Completeness Measure Thresholds...................................................... 13
Table 3. Provider Organization Profile Business Rule ......................................................................... 36
Table 4. MIROW BR 105 Details............................................................................................................ 37
Figure 2. Data Quality Input Screen (from Massachusetts IIS) .......................................................... 39
Figure 3. Data Quality Output – Overview Report (from Massachusetts IIS) ...................................... 40
Figure 4. Report Card – Completeness of Demographic Data (from Wisconsin IIS) ......................... 41
Figure 5. Report Card – Completeness of Immunization Data (from Wisconsin IIS) ......................... 42
Figure 6. Report Card – Invalid, Discontinued, and Unexpected Vaccine Dose (from Wisconsin IIS) ......................................................................................................................... 42
Figure 7. Report Card – VFC Related Data Quality (from Wisconsin IIS) .......................................... 43
Figure 8. Report Card – Recommendations based on Provider Organization’s Performance (from Wisconsin IIS) .................................................................................................................. 43
Figure 9. CIIS Data Validation Findings Report (from Colorado IIS) ............................................... 45
Figure 10. CIIS Data Validation Findings Report – Summary (from Colorado IIS) ............................ 46
Figure 11. Data Validation Findings Report – Patient Specific Review (from Colorado IIS) ............ 47
Figure 12. HL7 QA Stats Report (from New York City IIS) ................................................................. 48
The American Immunization Registry Association (AIRA) would like to acknowledge and thank the following individuals and organizations for their support and assistance with this important project:

The AIRA Onboarding Data Validation Workgroup who contributed their expertise through many hours of discussion and document review:

- Laura Pabst, Immunization Information System Support Branch/CDC Deputy Branch Chief
- Loren Rodgers, Immunization Information System Support Branch/Acting CDC Evaluation Team Lead
- LaTrece Harris, Immunization Information System Support Branch/CDC Evaluation Team
- Monica Hemming, Minnesota Department of Health/MIIC Data Quality Analyst
- Vanessa Willis, Colorado IIS Immunization Branch/Data Quality Coordinator
- Tracy Little, Oregon Immunization Program/ALERT IIS Interoperability Lead/Data Exchange Analyst
- Scott Benedict, Nebraska IIS/Data Exchange/Quality Coordinator
- Kimberly Lay, Massachusetts IIS/Data Quality Analyst and Trainer

The AIRA Assessment Steering Committee Members who developed the concept, oversaw process, and provided input at various stages of the effort.

The AIRA Board of Directors who provided input at various stages of the effort and/or reviewed and provided comment on the final guide:

- President Mary Woinarowicz, North Dakota Department of Health
- President-Elect Michelle Hood, Nebraska Department of Health and Human Services
- Immediate Past President Amy Metroka, New York City Department of Health and Mental Hygiene
- Secretary Jenne McKibben, Oregon Immunization Program
- Treasurer Beth English, Massachusetts Department of Public Health
- Directors Megan Meldrum, New York State Immunization Information System
  Kim Salisbury-Keith, Rhode Island Department of Health
  Bridget Ahrens, Vermont Immunization Registry
  Belinda Baker, Washington State Immunization Information System
  Bhavani Sathya, New Jersey Immunization Information System
  Baskar Krishnamoorthy, Florida Department of Health IIS
  Kevin Dombkowski, University of Michigan, Child Health Evaluation and Research Unit
  Brandy Altstadter, Scientific Technologies Corporation

ACKNOWLEDGEMENTS
The AIRA Staff who contributed to this document’s development:

- Sherry Riddick, Independent Public Health Consultant, who researched, wrote, and edited the guide
- Nichole Lambrecht, AIRA Senior Project Manager, who oversaw and managed the project, provided guidance and input, and edited the guide
- Alison Chi, AIRA Program Director, project leadership and oversight
- Eric Larson, AIRA Senior Technical Project Manager, provided expertise and guidance

Individuals that provided feedback during the external review process:

- Brandy Altstadter, Support Manager, Scientific Technologies Corporation
- Noam Arzt, President, HLN
- Cindy Findley, Director Division of Immunizations, Pennsylvania Department of Health
- Marlene Lugg, Senior Research Scientist, Research and Evaluation, Kaiser Permanente Southern California
- David Lyalin, CDC Informatics Team Lead (Acting), Immunization Information Systems Support Branch
- Rashid Malik, Database Manager, Maryland Dept. of Health & Mental Hygiene
- Nancy McConnell, IIS Manager, Utah SIIS Program
- Megan Meldrum, Research Scientist (Epidemiology), New York State Immunization Information System (NYSIIS)
- Craig Newman, Northrop Grumman, Supporting CDC/NCIRD/IISSB
- Heather Roth, Program Manager, Colorado Immunization Information System
- Kim Salisbury-Keith, KIDSNET Development Manager, RI Department of Health
- Rob Savage, Senior Information Technologist, Northrop Grumman, Supporting CDC/NCIRD/IISSB
- Dan Schwartz, Business Analyst Consultant, Immunization Program, Connecticut Department of Public Health
- Warren Williams, CDC Branch Chief, Immunization Information Systems Support Branch
Background

Over the past 20 years, the nation’s immunization information systems (IIS) have become increasingly integrated into the immunization programs they support. IIS also have gained respect in the health care provider community as a valued resource and multi-faceted tool in the provision of immunization services. IIS functionality now usually includes consolidating immunization-related patient information, clinical decision support, aggregate data reporting, vaccine inventory ordering and accountability, and many other tools.

The introduction of Meaningful Use (MU) in 2011 by the Centers for Medicare and Medicaid Services created an additional demand on IIS programs.¹ This demand resulted from a MU requirement that provider organizations exchange data electronically with certain public health systems, including IIS, in order to be eligible for the Meaningful Use Incentive Program.² IIS began receiving a high volume of requests from electronic health record (EHR) vendors wanting to test and prove their products’ abilities to exchange data electronically, and from provider organizations who wanted to establish electronic data exchange (EDE) in order to receive funds through the Incentive Program.

MU and the associated national movement toward electronic data exchange (EDE) present both challenges and opportunities for IIS. Challenges occur especially in the area of having adequate resources to meet national standards that are evolving and changing, and the high level of demand from provider organizations. Opportunities for IIS lie with the significant potential to receive more timely and more complete data than ever before. These opportunities also create a responsibility for IIS to reevaluate best ways to assess, monitor, and improve or maintain the quality of data.

Purpose

The purpose of this guide is to provide practical guidelines that IIS can use to ensure the quality of their data during the onboarding process. Also known as precertification,³ onboarding is the process of connecting, validating, and approving a new EDE source - from the moment of first contact with the provider organization to the go-live approval. This guide focuses on one aspect of onboarding - the data validation process. The data validation process assesses new sources of data for accuracy and completeness in a designated pre-production environment before allowing data into the IIS production system. High quality data in an IIS is important for the purposes of person matching and deduplication, immunization deduplication, accurate vaccine forecasting, and inventory management. To build on the work already done in this area and further reduce duplication of effort among IIS, the American Immunization Registry Association (AIRA) initiated this project in 2016 to research, review, and make recommendations for onboarding processes and practices specific to data validation.

This guide identifies and highlights proven practices used in the IIS community and gives IIS a resource to build or expand their onboarding data validation processes.

¹ EHR Incentives and Certifications: Meaningful Use Definition and Objectives. Available at HealthIT.gov website: https://www.healthit.gov/providers-professionals/meaningful-use-definition-objectives
² EHR Incentives and Certifications: EHR Incentive Programs. Available at HealthIT.gov website: https://www.healthit.gov/providers-professionals/ehr-incentive-programs
³ The term “precertification” was used in the MIROW Chapter 3: Data Quality Assurance in Immunization Information Systems: Incoming Data.
Audience

This document has been developed for IIS managers seeking guidance on data quality measures to implement for quality assurance/control in their IIS during the onboarding process. The document may also be valuable to the Centers for Disease Control and Prevention (CDC), National Center for Immunizations and Respiratory Diseases (NCIRD), Immunization Program Managers, IIS staff members, IIS vendors, EHR vendors, jurisdiction-specific information technology staff, national organizations supporting IIS, and other partner/policy makers.

Methodology

To create this guide, AIRA assembled a workgroup that consisted of subject matter experts (SMEs) from the IIS community, CDC partners, public health consultants, and AIRA staff (see list of participants in Acknowledgements section). During the initial phase of the project, existing IIS materials were gathered and reviewed to identify the relevant onboarding data validation practices. The materials included AIRA’s Modeling of Immunization Registry Operations Workgroup (MIROW) best practice guidelines on data quality, CDC Health Level 7 (HL7) implementation guides, and documents gathered directly from IIS programs. With support from a public health consultant and an AIRA project manager, the workgroup met via telephone once or twice a month from April through August of 2016. The workgroup reviewed materials and developed recommendations for the onboarding data validation guide. The consultant drafted and revised the guidelines based on input and feedback from the workgroup and others. Finally, the document was reviewed by AIRA staff, AIRA Board of Directors, and the IIS community, with the final version completed in August 2016.

Scope of Work

Onboarding of an EDE includes many steps - from the initial contact with a provider organization all the way to “go live” submission of data into the IIS production environment. While the focus of this guide is EDE with health care provider organizations, the highlighted processes can also apply to other data sources such as state vital statistics offices, health plans, and Medicaid. This guide focuses on the data validation process for provider organizations.

To set the context for data validation, Section 2 gives an overview of the major steps in the onboarding process. The remainder of the document covers activities that should occur only after data sources have received a test account, established connectivity to the IIS test environment, and received approval to begin testing. This guide will offer platform-neutral suggestions for data validation processes.

The workgroup specifically deemed the following topics out of scope for this document:

- The ongoing monitoring of incoming data and existing data
- Processes for engagement with provider organizations, EHRs, and health information exchanges (HIEs)
- Query/response messaging
- Structure and format of HL7 messages
PRIMARY RESOURCE MATERIALS

✔ AIRA Modeling of Immunization Registry Operations Workgroup Best Practices Guides
  □ Decrementing Inventory via Electronic Data Exchange, April 2015

✔ HL7 Version 2.5.1 Implementation Guide for Immunization Messaging, v 1.5. (Published and Posted Nov 5, 2014 by Centers for Disease Control and Prevention) and Addendum, Published July 2015

✔ IIS-specific data quality protocols and resources listed in Appendix B

---

4 Available on the AIRA website: http://www.immregistries.org/resources/aira-mirow
5 Available at the CDC website: http://www.cdc.gov/vaccines/programs/iis/technical-guidance/hl7.html
Onboarding Overview

Many IIS have a step-by-step process in place for getting a provider organization ready to send patient data from an EHR to the IIS. The nomenclature for these steps varies from IIS to IIS. The precise processes covered under each step may also vary. The following description is intended to provide a general overview of the onboarding process and Figure 1 provides a flow chart of the steps.

Onboarding starts with a process sometimes called DISCOVERY or PREPARATION where initial information about the provider organization is gathered to assess readiness in moving forward with the interface project. This may often be preceded by a formal registration process in which provider organizations have to officially register for onboarding. The next step usually involves PLANNING where information is shared to understand interface configuration needs and any modifications required in the EHR, the provider organization's business practice, or its clinical workflow. During planning, the provider organization or EHR representative should provide a CVX-to-vaccine mapping table that includes all vaccine types in use within the EHR at present as well as in the past. The IIS program should give the provider organization and/or the EHR vendor all documents needed for implementation of the interface, including the data validation process and criteria for data acceptance. A third step is DEVELOPMENT and TESTING where initial interface configuration is completed on both the IIS side and the provider organization side based on information gathered during the planning stage. The EHR’s CVX code table is examined by the IIS program to ensure its accuracy and completeness. Other coding elements may also be reviewed such as manufacturer, route, and site. Connectivity testing usually occurs at this time. Technical message review also occurs: HL7 messaging syntax and formatting requirements are evaluated to test the structural validity of the HL7 message and ensure the required elements are present. This can be an automated process to decrease the impact on IIS staff resources. Testing tools developed by the National Institute for Standards and Technology (NIST) are also available for IIS to use to validate vocabulary for valid HL7 field values. In fact, the IIS may require the EHR vendor and/or Provider Organization to pre-validate their message format with NIST. After messages pass the HL7 requirements, the IIS may perform additional content validation for each segment and subcomponent, as needed. Next, the DATA VALIDATION phase occurs. At this point, the EHR vendor and/or the provider organization will have demonstrated that they are capable of formatting a message correctly and that they will be submitting the proper data elements. Real patient data is submitted to the IIS test environment and reviewed by IIS staff to ensure quality standards are met. When the data has met the IIS program’s quality criteria, the IIS program makes the decision to GO LIVE. Final changes to the configuration are made to allow provider organization data to pass to the IIS production system. Although provider organization data now flows to the IIS production environment, data quality processes continue. An IIS interface requires ongoing, often daily, monitoring by the IIS and the provider organization. Although not covered in this guide, it is important to have processes in place for a continuous data quality improvement process.

Caveats: The steps listed above are neither all-inclusive nor mutually exclusive. The terminology for each step is not prescriptive and an IIS may use different terms for the steps. An IIS may have additional steps, different terms, and a different order of events for the overall onboarding process and that is perfectly acceptable.

It is also noteworthy that for many IIS the data quality checks occur simultaneously with the HL7 Development and Testing Phase. Appendix C contains examples of onboarding processes and checklists. Figure 1 depicts the steps described above. Steps 1 and 2 are out-of-scope for this guide. Step 3 includes some processes that are in scope and some that are not. Step 4 — Data Validation — is the primary focus of this guide. Step 5 includes important actions to take after data quality is approved and before data is allowed into the IIS production system.

⁶ NIST Immunization Test Suite: https://hl7v2-iz-r15-testing.nist.gov/iztool/#/home
⁷ See Appendix C-2 for a fuller description of possible steps in the onboarding process.
### Onboarding Process Steps for HL7 Electronic Data Exchange

#### Figure 1. Onboarding Process Steps for HL7 Electronic Data Exchange (Steps 3-5 are in scope for this guide)

<table>
<thead>
<tr>
<th>STEP 1</th>
<th>STEP 2</th>
<th>STEP 3</th>
<th>STEP 4</th>
<th>STEP 5</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>DISCOVERY</strong></td>
<td><strong>PLANNING</strong></td>
<td><strong>DEVELOPMENT &amp; TESTING</strong></td>
<td><strong>DATA VALIDATION</strong></td>
<td><strong>GO LIVE</strong></td>
</tr>
</tbody>
</table>
| Gather Information about provider readiness to move forward with interface | Hold Kick-off Call  
- Share information about the interface’s configuration needs  
- Identify modifications needed in the EHR and provider clinical workflow | Test technical aspects of data exchange work  
- Connectivity  
- HL7 messaging syntax, formatting requirements  
- Response messages from IIS to provider’s EHR  
- Messages corrected & resent until criteria met  
- CVX codes | Validate Data  
- Real patient data submitted by provider to IIS test site  
- Data quality evaluated by IIS for completeness and accuracy based on pre-established criteria  
- Data issues resolved by provider  
- Provider indicates readiness | Prepare to Go Live  
- Train provider staff  
- Change settings and configurations for Production environment  
- Determine Go Live date  
- Monitor closely for set period of time |

#### ACTIVITIES

- **STEP 1**: Confirm that provider is ready
- **STEP 2**: Ensure all parties have information needed to start development
- **STEP 3**: Ensure technical aspects or data exchange: connectivity works and HL7 messages are configured correctly
- **STEP 4**: Ensure quality of data meets IIS standards
- **STEP 5**: Ensure successful Electronic Data Exchange with minimal errors

#### GOALS

- **STEP 1**: Provider Readiness Checklist
- **STEP 2**: Local HL7 implementation guide from IIS EHR’s CVX code table  
  Onboarding Process Description
- **STEP 3**: Error reports
- **STEP 4**: Aggregate reports  
  Patient Level Reports  
  Examples of quality errors, missing fields
- **STEP 5**: Go Live Checklist  
  IIS contact information  
  Post Go Live monitoring protocols  
  Data Quality reports to use ongoing

#### JOB AIDS

- **STEP 1**: Provider Readiness Checklist
- **STEP 2**: Local HL7 implementation guide from IIS EHR’s CVX code table  
  Onboarding Process Description
- **STEP 3**: Error reports
- **STEP 4**: Aggregate reports  
  Patient Level Reports  
  Examples of quality errors, missing fields
- **STEP 5**: Go Live Checklist  
  IIS contact information  
  Post Go Live monitoring protocols  
  Data Quality reports to use ongoing
Source of Data for Validation Process

While “fake” or “test” data may have been used in the development and testing phase (e.g., in the HL7 message validation process), such data does not allow the IIS to accurately assess an organization’s readiness to go live. **Real patient data from the provider organization’s production EHR should be used during the validation phase.** The IIS should hold the data separate from their production database, usually in a test or pre-production site. Validation should be done for each provider organization separately, even those with the same EHR system, since implementation of an EHR may differ from one organization to another. Even within an organization, it is best to get data from each facility or physical site as usage of the EHR may vary. There may be some exceptions to this site-level requirement if all sites use the same version of the EHR or submit data through a common EHR-vendor hub. The need for site-level review may be reduced if the hub normalizes the data to meet IIS requirements. Still, if IIS resources allow, it is recommended to test each site’s data separately: how the EHR is actually used may vary from site to site.

Parameters for Data Set

The minimum data load required for a meaningful assessment depends on the size of the practice and the number of immunizations administered on a regular basis. The data should include the full set of vaccines administered across the age range covered by the practice and represent typical messaging at the provider organization’s office on a daily or weekly basis. While some IIS have determined that 250-1000 HL7 messages are needed for a thorough testing process, others have found that 50-100 patient records with vaccinations can provide a good idea of data quality.⁸

For smaller practices administering a low volume of vaccines, a numerical requirement may be unrealistic. Reviewing records over a period of time may work better than an absolute numerical requirement, with the advantage that the period of time can be adjusted according to the volume of vaccines administered. Real-time submission over a two- to four-week period usually provides enough data. If not, it may be more practical to ask for a historical data load covering a longer time period — such as the last quarter or year. For the smallest provider organizations, or those that only give the occasional vaccine, another option is for the IIS to give the provider organization a suite of test cases for entry into their EHR and subsequent submission to the IIS.

Whichever method the IIS chooses, it is essential that the sample data represent the provider organization’s vaccination practice, covering the full age range accepted by the IIS. Historical as well as administered vaccine doses should be sent for validation. **Test messages should be submitted to the IIS until all vaccine and demographic data issues have been resolved, the proportion of vaccines sent to the IIS is appropriate for the practice, and all vaccines administered are represented in the provider organization’s data received by the IIS.**

---

⁸ It may be advisable to exclude influenza messages from the count, especially during flu season. You may easily reach the numerical goal with an overabundance of flu vaccine data and an inadequate representation of the full panel of vaccines. Flu messages are still reviewed, just not counted toward the minimum number of records (if a minimum number has been established).
Data Quality Components

The three components of data quality are accuracy, completeness, and timeliness. During the onboarding process, **accuracy and completeness** of data are the primary concerns. **Timeliness** can best be evaluated later during ongoing data monitoring in the production environment. Accuracy assessment in the onboarding data validation phase is a search for suspect data, often revealed by cross-checking data elements for consistency and appropriateness, and by comparison to the originating medical record. Completeness in this context refers to the complete recording of all data elements for a particular patient and immunization event. Certain recommended fields may be important enough for an IIS to establish completeness thresholds before allowing a provider organization’s data into the IIS production environment. Completeness also refers to the capture of all expected immunizations based on the providers’ profile (i.e., not just sending pediatric doses but all doses administered).

Selecting Metrics and Thresholds

The metrics and thresholds selected will vary by provider organization type, capabilities of the EHR, IIS-specific needs, and other circumstances and local needs. In practice, some IIS have made their own determinations of which among the required fields are critical enough to cause automatic rejection of a message. Common must-have elements include first and last name, client ID (or medical record number), date of birth, vaccine type (CVX/NDC codes), and vaccination encounter date. Other fields that are important but not always required at the 100% level are gender and address. An IIS may want to set expected thresholds for other important data elements at a high level of completeness — perhaps 90-95% — before the interface is approved for production.

Determining the threshold of data completeness for non-required fields is somewhat arbitrary as there are no national standards in place. If the IIS program sets the threshold too high for non-critical fields, they run the risk of holding up progress to production indefinitely. If they do not set an expectation at all, they may never get the fields they want. As an overall rule of thumb, if an EHR captures a data element that has a corresponding field in the IIS, the IIS should encourage the provider organization to submit it, regardless of its priority.

In determining thresholds of data quality, each IIS program should examine the importance of each specific field to their own system and immunization program needs to determine when a data source is approved to go to production.

Accuracy Measures

The MIROW documents, referenced in the Introduction section, provide a solid foundation of best practices for incoming data quality. The 2008 MIROW guide “Data Quality Assurance in Immunization Information Systems: Incoming Data,” hereinafter referred to as the 2008 MIROW guide, contains a comprehensive description of relevant principles and business rules. The 2013 MIROW guide “Data Quality Assurance in Immunization Information Systems: Selected Aspects,” hereinafter referred to as the 2013 MIROW guide, updates, clarifies, and deletes some of the 2008 business rules. These best practice guidelines can be used by IIS to develop rules, protocols, and procedures that ensure the quality of data in the IIS. The business rules for “cross-check data validations” from these two documents are especially relevant to this guide and can assist with measurement of accuracy.

Cross-checks can be used to examine conflicts within a specific vaccine event, such as vaccine administration date preceding birth date, submission date preceding administration date, and consistency of manufacturer and CVX code within an event. See Appendix D-1 for a list of Selected Data Checks from the 2008 MIROW guide. In addition, comparing age at time of vaccination to the Advisory Committee on

Immunization Practices (ACIP) recommended schedule can reveal inconsistencies and potential inaccuracies related to minimum and maximum age for vaccines (including those due to actual clinical practice). In addition to cross-check validations, accuracy for certain individual fields can be reviewed for common data flaws. For example, screening for names of “unknown,” “test,” or “baby,” should be performed at some point in the data quality review.

Table 1 lists a subset of the 2008 and 2013 business rules, which were prioritized in the original MIROW documents, and reviewed, prioritized, and slightly modified by this guide’s workgroup. It may be very helpful for the reader to review the original MIROW documents for complete information on these and other business rules and data quality processes. Lower ranking business rules are not included in the table, but might be of higher priority to some IIS.

A total of 13 of the MIROW business rules received a high or medium priority rating by the workgroup. The nine high priority rules are listed in the first part of Table 1 (in business rule number order, not priority order). The four medium priority rules are at the bottom of the table.

10 See http://www.cdc.gov/vaccines/acip/recs/ for up-to-date ACIP Recommendations on Immunizations.
12 Note that BR 105 covers minimum/mandatory dataset. The elements listed there are superseded by the more up-to-date and comprehensive listing of required fields in HL7 Version 2.5.1 Implementation Guide, release 1.5. For details on the BR 105 dataset, see Appendix D-4.
### Table 1. Business Rules for Accuracy Validation

<table>
<thead>
<tr>
<th>Data Validation Check Description</th>
<th>Source of Rule</th>
<th>Rationale</th>
<th>Comments</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>HIGH PRIORITY</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
| Vaccination Encounter Date must not be before Patient Date of Birth | BR 101 | Indicates major data quality issue | Possible interpretations:  
- Either the Vaccination Encounter Date or Patient Date of Birth is incorrect (or both)  
- Patient identification is incorrect (e.g., could be a sibling) |
| Vaccination Encounter Date must be less than or equal to (before or the same as) the Submission Date | BR 103 | Indicates major data quality issue | Possible interpretations:  
- Vaccination Encounter Date is incorrect and EHR allows recording of encounter date in the future |
| Every administered vaccine should be recorded as a single Vaccination Event (e.g., combo vaccine should be recorded as 1 event rather than separate events for each component) | BR 107 | Indicates data quality or clinical quality issues  
Is a requirement for VFC accountability – affects inventory if using IIS for tracking | Possible interpretations:  
- Data entry error  
- Provider organization’s EHR may not be updated with the correct combo vaccine choice  
**Example:** Pentacel®, which contains DTaP, IPV, and Hib, should be submitted as one CVX code (one Vaccination Event) rather than one Vaccination Event for DTaP, one for IPV, and one for Hib (three Vaccination Events) |
| Vaccination Encounter Date should not be the same as the Patient Date of Birth unless it is on the list of vaccines recommended for administration on the date of birth, e.g., HepB | BR 114 | Indicates major data quality issue with date of birth, vaccine administration date, or vaccine code, or clinical practice issue | **Note:** At this time, only HepB is recommended before 1 month of age  
Possible interpretations:  
- Clinical practice error  
- Professional decision which differs from common practice  
- Date entry error with Vaccination Encounter Date, or Date of Birth  
- Provider organization’s EHR may not support data validation for these fields |
| Manufacturer and CVX Code should not contradict one another | BR 116 | Indicates a significant data quality issue – potential that wrong vaccine code has been entered, which may affect the decrementing of inventory  
If using IIS for vaccine accountability and inventory, this validation check is necessary | Possible interpretations:  
- Data entry error  
- Code translation (or other) error in software  
- Provider organization’s EHR system may not be up-to-date and may include incomplete or invalid values/choices  
- CVX code preferred (CPT code may be used if necessary). Vaccine type and Trade Name are not contained in HL7; vaccine type is determined by CVX and MVX (manufacturer) values within the message  
- NDC will be used in future and could be substituted for the CVX in this cross validation business rule |
<table>
<thead>
<tr>
<th>Data Validation Check Description</th>
<th>Source of Rule</th>
<th>Rationale</th>
<th>Comments</th>
</tr>
</thead>
<tbody>
<tr>
<td>Vaccination Encounter Date should not be after the lot number expiration date</td>
<td>BR 118</td>
<td>Indicates data quality issue with dates or lot numbers, or clinical practice</td>
<td>Possible interpretations:  - Expired vaccine was used  - Data entry error</td>
</tr>
<tr>
<td>Administered vaccinations coded with an &quot;unspecified&quot; CVX code (should have specific Vaccine Types, e.g., Hib PRP-OMP; unspecified vaccine types, e.g., Hib, unspecified formulation)</td>
<td>BR 121</td>
<td>Vaccine accountability/inventory may be affected if type is &quot;unspecified&quot;  Not specific enough to enable IIS forecaster to predict the next scheduled immunization correctly, possibly resulting in incorrect vaccination</td>
<td>Note: IIS should strongly encourage recording a specific vaccine type  Possible interpretations:  - The submitting system does not support the specific code so the recorder was forced to select the unspecified type  - The recorder did not know what specific vaccine was given  - The submitting system incorrectly reports the vaccine type  - The vaccine should have been recorded as historical rather than administered  - Clinical trials of new vaccines should be considered</td>
</tr>
<tr>
<td>Doses should not be recorded as given before the minimum patient age or after the maximum patient age for that particular vaccine</td>
<td>BR 130</td>
<td>Significant number of doses given too early or too late may be a data quality issue or clinical practice issue</td>
<td>Possible interpretations:  - May indicate clinical practice issues, including off-label use  - May indicate data entry or coding issues</td>
</tr>
</tbody>
</table>

**Implementation options** — an IIS may use its forecaster/clinical decision support tool to find “invalid” doses, or may develop separate queries to produce ongoing reports. See Appendix D-1 for implementation examples

**MEDIUM PRIORITY**

| Use of a Provider Organization Profile: If the Facility is a specific type of practice (e.g., pediatric), the currently administered vaccinations should match a pattern in similar practices, and/or should match a state-supplied vaccine list, especially in universal vaccine states for pediatric patients | BR 113 | Can be a very useful tool in data quality review once developed and automated | Notes: See Section 4 and Appendix D-2 for more information on developing provider organizations’ profiles  Requires a fair amount of work to implement but payoff may be worth it if automated reports can be created |

In universal vaccine states, where the state immunization program purchases vaccine for all childhood vaccines, the vaccines available to providers are predetermined by the state immunization program. Therefore, a profile can be created for the under 19 years of age population and applied to all providers serving children and enrolled in the state-supplied program. If vaccines are documented as administered that do not fall within this predetermined list an IIS can flag it as incorrect.

Possible interpretations: Variance from the expected profile could reflect actual clinical activity (e.g., inventory shortage) or manual coding errors
## Data Validation Process

### Red Book® Online Table — Status of Licensure and Recommendations for New Vaccines:


<table>
<thead>
<tr>
<th>Data Validation Check Description</th>
<th>Source of Rule</th>
<th>Rationale</th>
<th>Comments</th>
</tr>
</thead>
</table>
| The same patient should not receive the same antigen more than once in a single day | BR 117 | Indicates possible clinical or data entry issues | Possible interpretations:  
- Partial dose given first time — e.g., injection interrupted and not completed, and 2nd dose given in same visit  
- Two separate pediatric doses to comprise one adult dose and given to an adult  
- Poor clinical practice (Pediarix and IPV both given)  
- Data is from different patients |
| Route and Site should not contradict each other for a given Vaccine Type and Patient’s age | BR 119 | Indicates possible clinical or data entry issues | Possible interpretations:  
- Data entry error  
- Systematic code translation (or other) error in software  
- Clinical error  
- Provider organization’s EHR system may not be a current version and may be incomplete or include invalid values/choices  
- Provider organization’s EHR may not support data validation for these fields |
| Vaccination Encounter Date should be within the Vaccine Product License Date range — after the Vaccine Product License Begin Date and before the Vaccine Product License End Date | BR 120 | Doses should not be recorded as given before or after U.S. licensure — very likely coding or data entry error | Notes: Apply this rule to administered vaccines only, not historical  
Possible interpretations:  
- Incorrect coding  
- Data entry error  
- Unexpired vaccine used after Product License End Date.  
- Expired vaccine was used  
- Vaccine may have been given in another country with different availability, e.g., DTaP-Hib-IPV licensed in Canada and Mexico but not in USA at this point  
- Experimental/investigational drug trial  
- Vaccine code has been changed (re-used)  
Challenge: There is no single, authoritative source for many Vaccine Product License Dates. It may be necessary to compile the list from a variety of sources. One good place to start is the vaccine status table in the Red Book.¹³ |

Completeness Measures

An important measurement in data validation is completeness at the field level. Having complete demographic and immunization records ensures the adequacy of information needed to match patient records in the IIS. It also ensures that adequate data is available in the IIS for clinical-decision making by providers to determine which vaccines a patient may need. In addition, high quality complete data allows the IIS to be used for public health and population-level analyses. Increasingly, IIS are filling an important role in vaccine accountability and reporting, as well as monitoring vaccine uptake during outbreaks. These IIS roles and functions require specific data elements to meet federal standards.

The business rules defined in the 2008 and 2013 MIROW guides, explicitly and implicitly, describe some of the individual fields/data elements that are deemed necessary for a high quality record submission. Explicitly, business rules 104 and 105 list the minimum/mandatory required data items (e.g., name, date of birth, vaccination encounter date, vaccine type)\(^\text{14}\). Other MIROW business rules implicitly recommend the inclusion of specific fields in order to evaluate data accuracy through the cross-checking of data elements (e.g., lot number, manufacturer, route of administration).

In addition to the MIROW guides, two other documents provide valuable information when developing data element requirements, and were used to develop Table 2:

- CDC’s 2013-2017 IIS Functional Standards, Core Data Elements\(^\text{15}\)
- HL7 Version 2.5.1 Implementation Guide for Immunization Messaging, and Addendum, which defines the “usage” of each data element, segment, and message, in terms of whether or not they are required, conditional, or optional\(^\text{16}\)

Ultimately, the IIS may want to include in the analysis all Core Data Elements and all data elements defined as “Required” in the HL7 guide. Practically, however, most IIS will need to take an incremental approach to their ultimate goals, and start with those fields most important to achieving their data quality priorities. In determining completeness levels, each IIS program should examine the importance of each field to their own system and immunization program. Inability of a provider organization to meet a specific threshold need not prohibit permission to go live. That decision is made by the IIS program — the completeness levels listed in Table 2 are general recommendations, not absolutes.

Completeness demonstrates the percent of submitted records that contain data in various data fields/elements. For the purposes of Table 2, the completeness percentage is calculated by dividing the number of data fields/elements present (per data field/element) by the total number of demographic records or vaccination events (depending on data field/element) submitted. For example, if 100 vaccination events are submitted by a provider and 90 of those contain a CVX or NDC code, then the vaccine administered product type field has a completeness rate of 90% (90 complete divided by 100 total). Based on the threshold for this field in the table, that data source will not be allowed to go to production until the percentage reaches 100% (i.e., all vaccination events contain a CVX or NDC code). Note that the recommended completeness levels in Table 2 have been developed only in relation to the onboarding data validation process. Some, but not all, may apply to ongoing data quality monitoring. Additional recommendations will be developed in the future specific to ongoing data quality monitoring.

\(^{14}\) See Appendix D-4 for details of minimum/mandatory data in Business Rule 105.


\(^{16}\) HL7 Version 2.5.1 Implementation Guide for Immunization Messaging (Release 1.5) November 5, 2014.
### Table 2. Recommendations for Completeness Measure Thresholds

<table>
<thead>
<tr>
<th>Field/Element</th>
<th>Recommended Completeness Level¹⁸</th>
<th>Location in HL7 Messaging</th>
<th>Designation Usage in HL7</th>
<th>Source of Rule (other than HL7)</th>
<th>Rationale for Requiring High Completeness Level</th>
</tr>
</thead>
</table>
| Medical Record Number (AKA Client ID) | 100% | PID-3 | Required (R) | Workgroup | • Unique identifier of patient at provider organization level  
| | | | | | • Deduplication — matching to existing patient  
| | | | | | • May be leveraged by provider’s EHR in query messaging |
| Patient Name (Last, First) | 100% | PID-5 | Required (R) | BR 105 | • Component of minimum/mandatory dataset — see details in Appendix D-4 |
| Mother’s Maiden Name | 90% (if the patient is a minor) | PID-6 | Required but can be empty (RE) | Workgroup | • Deduplication for childhood population  
| | | | | | • 90% is gold standard level. Though currently difficult to achieve this mark, highly recommended as a goal because of its deduplication value |
| Patient Date of Birth | 100% | PID-7 | Required (R) | BR 105 | • Component of minimum/mandatory dataset — see details in Appendix D-4 |
| Patient Gender | 95-100% | PID-8 | Required (R) | Workgroup | • Deduplication  
| | | | | | • Possibility of future gender-specific vaccine recommendations  
| | | | | | **Note:** This changed from RE to R in the HL7 Addendum |
| Address | 95-100% | PID-11 | Required but can be empty (RE) | Workgroup | • Deduplication  
| | | | | | • Reminder-recall at IIS level  
| | | | | | • Coverage assessments at geographic level |
| Phone | 90-95% | PID-13 | Required but can be empty (RE) | Workgroup | • Deduplication  
| | | | | | • Reminder/recall — for IIS that use auto-dialers and potential text message reminders |

¹⁷ Note: when the IIS is used to meet the CDC vaccine tracking and accountability requirements, certain data elements must be present. Table 2 notes those elements required for VFC accountability. For more information, see the MIROW document, Decrementing Inventory via Electronic Data Exchange. April 2015. Available at the AIRA website: [http://www.immregistries.org/resources/aira-mirow](http://www.immregistries.org/resources/aira-mirow)  
¹⁸ Note that the HL7 Implementation Guide describes actions to take at the message level when fields are not present or empty but the recommended completeness level described here is the recommended threshold of completeness before allowing data source to go to production.
<table>
<thead>
<tr>
<th>Field/Element</th>
<th>Recommended Completeness Level¹⁻²</th>
<th>Location in HL7 Messaging</th>
<th>Designation Usage in HL7</th>
<th>Source of Rule (other than HL7)</th>
<th>Rationale for Requiring High Completeness Level</th>
</tr>
</thead>
<tbody>
<tr>
<td>Mother/Father/Guardian (Next of Kin)</td>
<td>90-100% (if the patient is a minor)</td>
<td>NK1-2</td>
<td>If NK1 segment is present, then NK1-2 segment is Required (R)</td>
<td>Workgroup</td>
<td>• Deduplication</td>
</tr>
<tr>
<td>Vaccination Encounter Date</td>
<td>100%</td>
<td>RXA-3</td>
<td>Required (R)</td>
<td>BR 105</td>
<td>• Component of minimum/mandatory dataset — see details in Appendix D-4</td>
</tr>
<tr>
<td>Vaccine Administered Product Type (CVX or NDC Code)</td>
<td>100%</td>
<td>RXA-5</td>
<td>Required (R)</td>
<td>BR 105</td>
<td>• Component of minimum/mandatory dataset — see details in Appendix D-4</td>
</tr>
<tr>
<td>Dosage (Administered Amount)</td>
<td>90%</td>
<td>RXA-6</td>
<td>Required (R)</td>
<td>Workgroup</td>
<td>• Accuracy cross-checks</td>
</tr>
<tr>
<td>Administered/Historical Indicator</td>
<td>100% for administered doses *See note below</td>
<td>RXA-9</td>
<td>Required (R) *See note below</td>
<td>BR 105</td>
<td>• Component of minimum/mandatory dataset — see details in Appendix D-4</td>
</tr>
<tr>
<td>Administering Provider Name</td>
<td>90% for administered doses *See note below</td>
<td>RXA-10</td>
<td>If dose is administered, then field is Required but can be empty (RE); otherwise it is Optional (O)</td>
<td>Workgroup</td>
<td>• May be VFC requirement in some states</td>
</tr>
<tr>
<td>Lot Numbers</td>
<td>100% for administered doses and if managing vaccine accountability and inventory in IIS *See note below</td>
<td>RXA-15</td>
<td>If dose is administered, then field is Required (R); otherwise it is Optional (O)</td>
<td>BR 105</td>
<td>• Component of minimum/mandatory dataset – see details in Appendix D-4</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>• Tracking doses back to patient when lot recall occurs so patients can be notified and revaccinated if required</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>• Managing inventory</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>• Cross-checking accuracy of vaccine type</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>• VFC Requirement</td>
</tr>
</tbody>
</table>
## SECTION 3: Data Validation Process

<table>
<thead>
<tr>
<th>Field/Element</th>
<th>Recommended Completeness Level</th>
<th>Location in HL7 Messaging</th>
<th>Designation Usage in HL7</th>
<th>Source of Rule (other than HL7)</th>
<th>Rationale for Requiring High Completeness Level</th>
</tr>
</thead>
</table>
| Vaccine Lot Expiration Date | 90% for administered doses. *See note below | RXA-16 | If dose is administered, then field is Required but can be empty (RE); otherwise it is Optional (O) | BR-118 cross-check | • Useful for data quality checks within a practice, accuracy cross-checks, and clinical practice review  
• VFC requirement |
| Manufacturer | 95-100% for administered doses and if managing vaccine accountability/inventory in IIS. *See note below | RXA-17 | If dose is administered, then field is Required (R); otherwise it is Optional (O) | BR 116 cross-check IIS may be able to validate accuracy of data by cross checking manufacturer against vaccine type (CVX) or lot number | • Tracking doses back to patient when lot recall occurs  
• If using IIS for vaccine accountability with the VFC program  
• Managing inventory  
• Cross-checking accuracy of vaccine type |
| Route | 90% | RXR-1 | Required (R) if RXR segment is sent | BR 119 cross-check | • Accuracy cross-checks  
• Clinical practice review |
| Body Site | 90% | RXR-2 | Required but can be empty (RE) | BR 119 cross-check | • Accuracy cross-checks  
• Clinical practice review |
| VFC Eligibility (if practice is participating in the VFC program) Note: The HL7 guide refers to this data element as the Vaccine Funding Program Eligibility | 90% | OBX -3 LOINC Code 64994-7 | If OBX segment is present and if dose is administered, then field is Required but can be empty (RE) | BR 122 | • Enables immunization program to determine amount of vaccine supply needed to immunize the under 19 years-old population  
• This a state-specific business rule — some states allow this; some do not  
• This BR is more about program’s policy, and less about data quality  
• State-supplied vaccine (such as VFC vaccine) should be given to eligible children; this is specific to the vaccine |

*See note below
### Field/Element

<table>
<thead>
<tr>
<th>Field/Element</th>
<th>Recommended Completeness Level</th>
<th>Location in HL7 Messaging</th>
<th>Designation Usage in HL7</th>
<th>Source of Rule (other than HL7)</th>
<th>Rationale for Requiring High Completeness Level</th>
</tr>
</thead>
</table>
| Vaccine Funding Source        | 90%                            | OBX-3 LOINC Code 30963-3  | Optional                 | Workgroup                       | • If vaccine for the immunization comes from the VFC program, it is a VFC requirement to document the funding source  
• Can be used when reviewing inventory borrowing logs |
| VIS-related:                  |                                |                           |                          |                                | Federal requirement to record VIS publication date and date document provided to patient/parent. If not recorded in the IIS, must be present in some form of permanent medical record maintained by the provider |
  - VIS vaccine type           | 90%                            | OBX-3 LOINC Codes         | If this is an administered vaccine, then VIS information is required (R). See CDC HL7 implementation guide for more details¹⁹ | Federal law requires the provision of the Vaccine Information Statement for most childhood vaccines |
  - VIS publication date        |                                 | VIS vaccine type: 30956-7 |                          |                                |                                                 |
  - VIS presentation date (date VIS form provided to patient) |                                | VIS publication date: 29768-9 |                          |                                |                                                 |
  - VIS presentation date (date VIS form provided to patient) |                                | Presentation date: 29769-7 |                          |                                |                                                 |

* Note: The administered/historical indicator (RXA-9) is required except when the dose is refused or not administered. If the vaccine was refused or not administered, it is optional.

Methodology

Aggregate data review

Early in the data validation process, an IIS may choose to run some basic metric queries on counts of vaccines administered by age, and by time period such as week, month, or year. A count and percentage of invalid doses will also be helpful. Such broad reports can give an early indication of egregious problems that can be corrected before getting into the more time-intensive data quality processes. For example, low numbers of expected vaccine types could be an indication of coding issues in the EHR or consistent data entry selection errors. It is worth noting an initial data validation step that an IIS can choose to perform even before the HL7 technical message review occurs. In this very early step, the provider organization submits a large extract file in the format preferred by the IIS - at this point it could be in flat file or HL7 format. A review of the data can help uncover and resolve basic and widespread data quality issues before proceeding to the subsequent onboarding validation. See Appendix F-5 for more information.

Some IIS have automated reports that can be run at the provider organization or site level by IIS staff. These reports can aid in the discovery of data anomalies or errors and can reduce the burden on IIS staff resources. Reports that break down vaccines administered by age and dose allow the reviewer to identify patterns of error related to vaccine type and age appropriateness. This could include a summary of vaccinations given outside of the recommended schedule, such as those given too soon, too young, or too old, missing and over- or under-represented vaccine types, vaccine types that have an incorrect manufacturer, and vaccine types that are “unspecified.” It is important that reports passed on to the provider organizations include examples of data issues at the patient level so the clinic can investigate.

The clinic may find they need to change their workflow, data entry protocols, clinical practices, or ask the EHR vendor to make changes. If feasible, making these reports accessible for provider organizations to run themselves can help with clinical staff investment in the process.

Examples from IIS of processes for aggregate reports:

In Missouri, after a provider organization has successfully sent data to test for a period of time (without errors identified in the HL7 review process), IIS staff run a series of Statistical Analysis System (SAS) programs to cross-check the data and produce reports. These programs check that all standard codes are valid and calculate completeness rates of specific demographic and immunization data elements. The programs also cross-check CVX vaccine codes with manufacturers, vaccine codes with ACIP minimum and maximum ages, and appropriate route/body site for the vaccine type.19

In Minnesota, the validation process involves creating two extract files (one client and one immunization) and importing the data into an Access database quality assessment tool. A series of queries are run based on the imported data: count of shots, review of CVX codes, quality checks related to ACIP inconsistencies, and others. Additionally, a random sample of patients is created for auditing against the medical record (see next section).20

In Massachusetts, a quality metric tool is used early in the testing process. This tool is an SQL based query that can be run on the database to measure overall validity of the data: counts of vaccine types

---

20 Email from Monica Hemming, MIIC Data Quality Analyst, Minnesota Department of Health, 4/20/16.
administered by age, counts of vaccines administered by year, and the count of invalid/valid doses with certain thresholds. In addition, a data quality overview report has been developed which provides a summary of the incoming data. The counts and percentages provide information on potential red flags in the overall data. An example of the overview report is included in Appendix F-1.

Appendix F contains a sample of data quality reports used by different IIS.

Individual Patient Record Review

Some IIS choose to compare IIS data to the originating medical record in order to complete the data validation process. If time and resources are available, this can be an excellent data quality strategy. Most commonly, patients are selected for individual review based on identified errors or suspicious data. In addition, some IIS do a random selection of patients, with the number and age cohort varying by IIS, but usually in the 20-40 range. Although quite time-consuming, manual review of patient records can be valuable in revealing problems that are not obvious in an aggregate review. Working with a provider organization’s clinical staff will help identify the source of problems, whether data entry error, incorrect mapping, or actual clinical practice. In addition, clinical staff may identify other data problems not visible by a review of the HL7 messages or aggregate reports. Engaging clinic staff in the review process will also help train them for ongoing data quality monitoring as they will ultimately ‘own’ that responsibility.

The number of records reviewed and the process for doing so depends on the IIS’ available resources. One method involves requesting the clinic staff to print out copies of specific patient records from their EHR, and submit them to immunization program staff for comparison. Another method, less resource-intensive on the IIS, has the IIS provide the clinic with the list of patient records, and ask the clinic staff to do the review between the two systems. In doing the comparison record review, the IIS program may choose to review all data elements available, or in the interest of time and efficiency, choose to select a subset of the elements deemed most important to the IIS.

The following list provides an example of data elements to review when comparing medical records to IIS data:

- Client ID
- Patient’s first and last name
- Patient’s gender
- Patient’s date of birth
- Patient’s address and phone number
- Patient’s parent/guardian name (if the patient is a minor)
- Vaccination administration dates
- Vaccine names
- CVX codes
- Vaccine lot numbers (if administered by site)
- Expiration Dates
- Vaccine dosage mL (if administered by site)
- Manufacturer’s code or Trade name (if administered by site)
- Administered route and site (if administered by site)
- Name of administering clinic/hospital
- Vaccine Eligibility (for state supplied vaccine programs such as VFC)
- Vaccine Funding Source
- Vaccine Information Statement (VIS) Edition Date and Date it was Given

---

22 Email from Kimberly Lay, Data Quality Coordinator, Massachusetts Immunization Information System (MIIS), Massachusetts Department of Public Health, 4/15/16.
Use of Provider Organization Profiles

Each provider organization practice, depending on the age and type of population served, is expected to administer a certain range of vaccine types in specific proportions. The IIS can maintain typical profiles for different types of practices – such as pediatric, adult, OB-GYN – and assign a profile type to each practice. The provider organization profile then can be compared to incoming data files for discrepancies. When the two do not match, problems likely exist, including miscoding issues, missing vaccine codes, and systematic data entry errors (e.g., entering a pneumococcal polysaccharide instead of a conjugate vaccine). This comparison will also detect unusual but accurate patterns of administration due to temporary vaccine shortages, a shift in the provider organization population or unusual clinical practice.

Profiles can be developed in different ways. The 2008 MIROW guide provides the following suggestions, with more details available in Appendix D-2:

1. Statistically develop provider organization profiles by averaging data in the IIS from all provider organizations of the same type, and compare a specific provider organization’s vaccine distribution to that of the average distribution for that type of provider organization. Large deviations from the average profile may indicate problems, particularly errors or omissions in vaccine codes.

2. Develop distributions based on the “ideal” vaccination pattern, i.e., if the population in question receives all recommended immunizations, and compare each provider organization’s pattern to that “ideal” distribution.

3. Establish a provider organization-specific vaccine distribution profile. In this approach, each provider organization would have its own distribution, which would be developed with IIS staff. It would involve working with each provider organization to understand and quantify their clinical practice and establish a provider organization-specific profile. Every data file would be compared to that distribution to ensure that no deviations are observed.

A provider organization-specific profile as described in #3 can be developed for VFC provider organizations, especially in a universal distribution state. In this case, the IIS (or the immunization program) has access to the provider organization’s ordering and usage information which can form the basis for the profile. This will be easiest to accomplish for provider organizations that have a history of using the IIS to manage their vaccines. It may be a process that is more suited to the ongoing monitoring of data quality rather than the initial data validation process described here.

Roles

Defining the role of each entity/stakeholder should occur in the Discovery or Planning stage of the onboarding process. Representatives of the EHR vendor, the provider organization, and the IIS should all participate. On the provider organization side, it is crucial to have the participation of clinical staff to address workflow issues and handle data quality reviews. Since provider organizations may have different system configurations at each site, it is important to treat each site’s data separately and usually to have representatives from each site participating in the data review. In some situations, there may be separate staff available for each function. In others, one person may be responsible for most or even all of the onboarding and data validation processes.

Within the IIS program, specific designation of roles and job titles vary from state to state, from program to program. Organizational structures vary and relationships among the Immunization Program, the IIS, and, in some cases, a separate information technology (IT) department, will inform how roles are broken out. In addition, the IIS vendor may take responsibility for some or all of the onboarding process.

25 For more details on this approach, see 2008 MIROW Guide, p. 98-99, “Appendix F. A possible statistical approach to an automated methodology for utilization of providers’ profiles for analysis of reported data quality.”
Here is a breakdown of the most common job categories/titles along with their major tasks:

**IIS Roles:**
- Project manager/data exchange coordinator — oversight and coordination of each interface
- Technical team member, interface coordinator — connectivity and configuration of each interface, testing HL7 messages²⁶
- Data exchange analyst/data quality analyst - data validation assessment and follow-up with provider organization — could be a shared responsibility between technical team and program team²⁷
- Immunization Program — input on VFC requirements as needed

**Provider Organization Roles:**
- Clinical information or health information analyst — (mostly found in larger provider organizations) — development of interface on the EHR side
- Clinical staff — data quality review, verification that patient and vaccination information is complete and accurate, educating all clinic staff in the proper use of the EHR and its role in data quality
- Clinical champion — (could be clinical staff or MU-dedicated staff member) - responsible for keeping the process moving forward on the provider organization side

**EHR Roles:**
- Project manager/implementation manager — liaison with EHR technical team. Assurance that all coding and development within the EHR database and application are correct for the interface (These EHR roles may be filled by the provider organization — see first bullet above under Provider Organization Roles)

### HELPFUL HINTS for Successful Implementation of Data Validation Processes:

- Start incrementally if new to an onboarding data validation process, first establishing a base level of data validation, then adding to it as capacity allows.
- Adhere as closely as possible to national specifications for incoming messages (VXUs) as well as outgoing messages (ACKs).
- Have at least one team member who is fluent in HL7 messaging.
- Provide a local specification guide distilled to local variations as a companion to the national HL7 implementation guide.
- Have a clear policy statement on data quality requirements, and provide a data quality best practices guide to EHR vendors and provider organizations.
- Meet a national or vendor-accepted standard for transport.
- Document internal data validation processes.
- Automate data quality reports in the pre-production environment to save IIS staff time.
- Provide reports to provider organizations throughout the testing process.
- Engage clinic staff to help with review of data and patient records.
- Make data quality reports available to provider organizations to run through a user interface as feasible, with priority on availability in the production system and availability in pre-production as possible.
- Understand how your programmatic requirements may impact how you handle eventual production data.
- Take into account differences among EHR capabilities and what can be realistically required — striking a balance of not requiring so much that nobody can do it, but also getting what is really needed for program operations.

²⁶ Also see IIS Interface Analyst Sample Role Description, Public Health Informatics Institute, March 2016. [http://www.immregistries.org/resources/iis-workforce](http://www.immregistries.org/resources/iis-workforce)
²⁷ Also see IIS Data Quality Analyst Sample Role Description, Public Health Informatics Institute, March 2016. [http://www.immregistries.org/resources/iis-workforce](http://www.immregistries.org/resources/iis-workforce)
Other Issues

Manual triggers to submit data: In the discovery and planning phases, IIS staff should clarify how HL7 messaging is triggered. It may come to light that the EHR system requires manual action to send an HL7 message to the IIS. Most systems now have automated processes, but some do not and require human intervention to trigger the “send.” During the testing and validation phases, IIS staff should confirm the mode of message initiation. Where a manual trigger is needed, the IIS should require that the provider organizations have a written policy and staff training protocols addressing this subject. IIS staff should pay close attention to frequency of data submission in the first few weeks after going live.

Automatic triggers that submit administered vaccine erroneously: In some systems, an automatic trigger sends a vaccination event that is planned, but the actual administration does not occur due to deferral or refusal. If the submission date and vaccination date are the same, this may not be easily identified by the IIS. It is important to identify this possible scenario in the discovery phase of onboarding.

Adding additional sites: Multi-site organizations may want to add new facilities to an existing approved interface. In many cases, it is advisable to require each site or facility to go through a data validation process before approving the move to the production system. The new site should complete the same testing protocols as other sites within the organization, submitting enough data to have a meaningful data quality assessment. Staff at the new facility may also need training specific to the IIS. In cases of very large provider organizations that manage their own EHR systems internally, that have staff dedicated to oversight and training of personnel, it may be unnecessary to require a separate validation process for each site.

Working with a third party entity such as a Health Information Exchange (HIE) or an EHR hub presents its own challenges and processes relevant to data validation. Some third parties function as a simple pass-through from provider organization to IIS and back, without touching the data. Others transform the data through a program or script that assures it matches submission requirements for the IIS. The important thing is to have good and clear communication so that all parties, including provider organizations, know who is responsible for each function. It is especially vital to clarify and document who is responsible for the data quality checks and for follow-up with provider organizations.
Preparations to Go Live

It may be helpful to use a Go Live checklist as you near the final stages of onboarding. The checklist can include final steps to get ready for moving to Production as well as a plan for the organization to follow after going live.

See Appendix C-3 for example of a Go Live checklist.

Final preparations prior to the interface going live should include training of the provider organization staff. Training can include general IIS training if needed, as well as specialized training related to HL7 messaging, error reports, and ongoing data validation. Final instructions on connecting to the IIS production environment should be provided to the provider organization and/or EHR representative. A go live date and time should be selected when provider organization and IIS staff are available to monitor and trouble-shoot any issues that arise. Final changes to the configuration are made to allow provider organization data to pass to the IIS production system.

Short Term Data Quality Review after Go Live

The IIS program should establish a protocol for close review of data for a period of time (often 30-60 days) after go live. The IIS can monitor by looking at a sampling of messages periodically and by using data quality metric tools and reports. Provider organizations can monitor by assigning staff to review IIS response messages (ACKs) that indicate errors and rejections. They should also log into the IIS regularly to compare data between the IIS and EHR. IIS data quality reports that can be run by provider organization staff are especially helpful. A list of provider organization expectations should include:

- Consistently reviewing the warning/error report and promptly fixing any issues
- Resending any failed messages after correcting the problem with the message (in response to ACK notifications)
- Keeping the EHR application up-to-date and notifying IIS of any upgrades or system changes (which can occasionally create unexpected problems)
- Ensuring CVX, NDC, and MVX code tables and VIS publication dates are current with CDC-provided updates
- Ensuring the interface continues to run at all times (especially after a power outage, or after installing or upgrading servers and software

An example of a “report card” approach is included in Appendix F-2. Use of a report card or other data quality reports during this time period identifies: transmission, mapping and/or coding issues that were overlooked during onboarding, and use of vaccine that is unexpected or inappropriate. This approach is most successful for improving data quality when there is provider organization office staff buy-in.

See Appendix F-2 for an example of a report card.
This guide has focused on one aspect of onboarding – the data validation process. Validating data during the period of onboarding offers an opportunity to scrutinize the data at a level impractical during ongoing data processing. Issues that are otherwise difficult to identify can be isolated and addressed during this testing period. This will help ensure a high quality of data, once approved and allowed into the IIS production environment. Cleaning erroneous data from the production system is difficult and resource intensive; it is preferable to not allow these data to be accepted in the first place.

The guide has included practical recommendations for the implementation of data quality protocols. Recommendations range from the importance of using real patient data in the validation process, to accuracy assessments through data cross-checks, and to completeness assessments at the field level. Business rules and data elements have been prioritized to assist IIS programs in the selection of data quality metrics and criteria. Examples of approaches taken by various IIS around the country are included, and sample data quality reports can be found in Appendix F.

This guide was developed in expectation that each IIS program will adjust the implementation of the recommended business rules and practices to their own specific needs and unique implementation concerns. The list of recommendations presented here is not exhaustive. Individual IIS may choose to implement additional rules based on their unique requirements. The recommendations and examples represent an attempt to balance ideal practices with pragmatic considerations of what is possible within the IIS.
## Appendix A–1: Abbreviations

<table>
<thead>
<tr>
<th>ACRONYMS</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>ACIP</td>
<td>Advisory Committee on Immunization Practices</td>
</tr>
<tr>
<td>AIRA</td>
<td>American Immunization Registry Association</td>
</tr>
<tr>
<td>BR</td>
<td>Business Rule</td>
</tr>
<tr>
<td>CDC</td>
<td>Centers for Disease Control and Prevention</td>
</tr>
<tr>
<td>CMS</td>
<td>Centers for Medicare and Medicaid Services</td>
</tr>
<tr>
<td>CPT code</td>
<td>Current Procedural Terminology code</td>
</tr>
<tr>
<td>EMR/EHR</td>
<td>Electronic Medical Record/Electronic Health Record</td>
</tr>
<tr>
<td>DOB</td>
<td>Date of Birth</td>
</tr>
<tr>
<td>EDE</td>
<td>Electronic Data Exchange</td>
</tr>
<tr>
<td>EHR</td>
<td>Electronic Health Record</td>
</tr>
<tr>
<td>HIE</td>
<td>Health Information Exchange</td>
</tr>
<tr>
<td>HL7</td>
<td>Health Level Seven International</td>
</tr>
<tr>
<td>IIS</td>
<td>Immunization Information System</td>
</tr>
<tr>
<td>IIS-AO</td>
<td>IIS-Authorized Organization</td>
</tr>
<tr>
<td>LOINC</td>
<td>Logical Observation Identifiers Names and Codes</td>
</tr>
<tr>
<td>MIROW</td>
<td>Modeling of Immunization Registry Operations Work Group (AIRA section)</td>
</tr>
<tr>
<td>NCIRD</td>
<td>National Center for Immunizations and Respiratory Diseases</td>
</tr>
<tr>
<td>NDC</td>
<td>National Drug Code</td>
</tr>
<tr>
<td>SME</td>
<td>Subject Matter Expert</td>
</tr>
<tr>
<td>UI</td>
<td>User Interface</td>
</tr>
<tr>
<td>VFC</td>
<td>Vaccines for Children</td>
</tr>
<tr>
<td>VIS</td>
<td>Vaccine Information Statement</td>
</tr>
</tbody>
</table>
CPT – A numerical string that describes the procedure (a billable service) of administering a vaccine. Current Procedural Terminology codes are developed by the American Medical Association to bill for medical or psychiatric procedures performed by health care practitioners. See http://www2a.cdc.gov/vaccines/iis/iisstandards/vaccines.asp?rpt=cpt

CVX – A numerical code that describes a Vaccine Type. CVX codes are assigned by CDC to support electronic messaging of immunization histories via HL7. See http://www2a.cdc.gov/vaccines/iis/iisstandards/vaccines.asp?rpt=cvx. Vaccine Type maps to a CVX code. There is normally one CVX code per one Vaccine Type.

EHR System – Electronic health records system utilized by the provider organization. There is no commonly understood distinction between the concepts of an electronic health record and an electronic medical record, and no such distinction has been made uniformly in the literature. For the purposes of this project, the term “EHR system” or simply “EHR” will be used to refer to both EHR and EMR systems.

HL7 Specification – Health Level Seven (HL7) is a nationally recognized standard for electronic data exchange between systems housing health care data. See description in Appendix A–3 for more details.

IIS-Authorized Organization – An organization that has an agreement with the IIS which allows submittal and/or retrieval of the IIS data.

LOINC – Provides a universal standard for identifying laboratory observations within an OBX segment in an HL7-based data exchange.

Lot Number – The number assigned by the manufacturer to a specific batch of Vaccine Product Type. Lot Number can be used by IIS to track administered vaccines.

Lot Number Expiration Date – This is the expiration date assigned to each lot of vaccine by the manufacturer. Beyond this date, the vaccine should no longer be administered.

Manufacturer (MVX code) – Manufacturer is the organization that manufactures a specific vaccine. vaccines. MVX is the code used in an HL7 message that identifies the manufacturer.

Meaningful Use – Meaningful use is using certified electronic health record (EHR) technology to: Improve quality, safety, efficiency, and reduce health disparities, engage patients and family, improve care coordination, and population and public health, maintain privacy and security of patient health information. See https://www.healthit.gov/providers-professionals/meaningful-use-definition-objectives

National Drug Code (NDC) – NDC is defined as a unique numeric identifier of the Vaccine Product Type. Each drug product is assigned a unique three–segment number. This number, known as the NDC, identifies the labeler (manufacturer or distributor), product, and trade name.

OBX – In HL7 the OBX is used to transmit a single observation or observation fragment.

Onboarding – Process of bringing a new data exchange source from first contact to going live with the exchange.

Provider Organization – An organization that provides vaccination services or is “accountable” for an entity that provides vaccination services. A Provider Organization can be a solo practice with one clinical site or can contain a collection of related Providers (e.g., clinicians – physicians, nurses) with multiple sites.

Trade Name – Indicates the manufacturer’s proprietary name for a product and, in some cases, its intended use (e.g., Adults, Pediatrics) is included in the name.

Vaccination Encounter Date – Synonymous with Vaccination Administration Date.
**Vaccine Product Type** – A category of the vaccine product that is ordered, shipped, administered, etc. Vaccine Product Type, for inventory tracking/management purposes, is characterized by the NDC code. Vaccine Product Type, for immunization tracking purposes, is characterized by the Vaccine Type (or CVX code, or CPT code), Manufacturer (MVX code), and Trade Name.

**Vaccine Type** – The Vaccine Type is defined as a category of Vaccine. A single Vaccine Type may be associated with many Vaccine Product Types (i.e., different manufacturers, different packaging).

**Appendix A–3: Health Level 7 (HL7) Description**

Health Level Seven (HL7)²⁸ is a nationally recognized standard for electronic data exchange between systems housing health care data. In a collaborative effort between the Centers for Disease Control & Prevention (CDC) and AIRA, an HL7 implementation guide (based on HL7 Version 2.5.1) has been developed, maintained, and updated to facilitate the exchange of immunization records between different systems. According to the HL7 Version 2.5.1 Implementation Guide, "the HL7 standard is a key factor that supports this two-way exchange of information because it defines a syntax or grammar for formulating the messages that carry this information. It further describes a standard vocabulary that is used in these messages. It does not depend on specific software, that is, it is platform independent."²⁹ In a collaborative effort between the Centers for Disease Control & Prevention (CDC) and AIRA, an HL7 implementation guide has been developed, maintained, and updated to facilitate the exchange of immunization records between different systems.

The scope of the HL7 guide includes:³⁰

- Sending and receiving immunization histories events for individuals
- Requesting immunization histories for individuals
- Requesting an evaluated history and forecast for individuals
- Responding to requests for complete immunization histories by returning immunization histories
- Responding to requests for evaluated history and forecast
- Acknowledging receipt of immunization histories and requests for immunization histories
- Reporting errors in the messaging process
- Sending observations about an immunization event (this may include patient eligibility for a funding program, reactions, forecasts, and evaluations)

²⁸ See [www.HL7.org](http://www.HL7.org) for more information about Health Level Seven.
³⁰ Ibid, p. 3.
Appendix B. References


11. EHR Incentives and Certifications: Meaningful Use Definition and Objectives. Available at HealthIT.gov website: https://www.healthit.gov/providers-professionals/meaningful-use-definition-objectives

12. EHR Incentives and Certifications: EHR Incentive Programs. Available at HealthIT.gov website: https://www.healthit.gov/providers-professionals/ehr-incentive-programs


Appendix C-1: Sample of Onboarding Readiness Checklist for Provider Organizations

- Provider Organization is active in the IIS and has recently submitted all documents required to begin work on an HL7 interface.

- Technical support is available to the Provider Organization and includes in-depth knowledge of translating and correcting HL7 message errors. This support could be from internal staff, the EHR vendor, or a third party.

- EHR vendor has a history of supporting the Provider Organization when technical assistance is needed regarding their product.

- EHR system has been in use at the Provider Organization for at least x months.

- EHR system is able to send and receive electronic data using HL7 version 2.5.1 messages.

- EHR system is capable of sending valid codes in accordance with the CDC Implementation Guide and local state requirements.

- EHR system is capable of capturing and sending IIS expected data fields. Expected data fields include all data elements listed in the local state requirements.

- Provider Organization is committed to an ongoing quality data exchange and will provide staff time and other resources necessary for efforts to develop, test, implement, and maintain an interface for interoperability with the IIS.

- Provider Organization understands that data needs may change, and request to adapt content and processes in the future may be made by the IIS Team as data requirements change.

---

Appendix C-2: Sample Onboarding Process Document

This document describes in detail the various stages involved when developing an interface with the IIS.³²

NOTE: The steps outlined below must be completed for each individual site regardless of the status of another site within the same Provider Organization. For large organizations, there may be a point person for the organization as a whole, and it is important to involve Site-specific personnel at the appropriate time.

1. DISCOVERY/PREPARATION – Initial information about the Provider Organization and its Sites is gathered to assess readiness in moving forward with the interface project.

1.1. The Provider Organization and/or Site complete the IIS Provider Organization Onboarding Readiness Checklist, sent by the IIS Team. Based on the results, the Site will:

- Determine it is ready to move forward with the project, and notify IIS team to continue to Step 1.2.
- Determine it is not yet ready to move forward with the project. The Site, in conjunction with the IIS Team and the EHR Vendor as necessary, will discuss barriers and develop a readiness action plan.

1.2. The IIS Team will:

- Contact the Site to discuss moving the project forward to the Planning stage, which includes discussing the IIS Provider Organization Onboarding Readiness Checklist, planning a kick-off call and EHR demonstration.
- Provide the Site with a copy of the IIS HL7 Implementation Guide and other relevant documents such as data validation and data quality requirements and criteria.
- Verify that the Provider Organization and/or Site have an up-to-date IIS Provider Organization Enrollment Agreement in place.

2. PLANNING – Information is gathered to understand the interface’s individual configuration needs and any modifications required in the EHR, in the Site’s business practice, or in the Site’s staff workflow or training. Steps 2.1 and 2.2 may be combined if it is more convenient for all parties involved. The EHR Vendor is typically not involved at this stage, but may be included at the request of the Site.

2.1. A kick-off call is held between the IIS Team, the Provider Organization/Site Contact, technology or project management staff from the Provider Organization and/or Site, and appropriate relevant clinical staff that oversee or use the EHR for vaccination data entry. During the call:

- The group discusses the project timeline, including ongoing meetings, roles, communications, milestones, and file frequency.
- The Site Contact completes the IIS HL7 Site Profile, used by the IIS Team to track details such as the Site’s interface configuration, training needs, or issues/opportunities identified during the kick-off call. Site staff should begin filling out the profile prior to the kick-off call, which will assist Site staff in understanding the type of information discussed on the call and will help ensure the correct Site staff members are present for the call.
- The IIS Team provides IIS-related education to the Site staff present.
- The IIS Team reviews the IIS Data Reporting Guidelines.

2.2. At least one Site staff member familiar with the day-to-day use of the EHR (multiple if different EHR modules are handled by different staff), demonstrates to the IIS Team how it is utilized on a daily basis (using a remote web-based meeting tool). In order to clarify any ambiguities

documented in the IIS HL7 Site Profile, the IIS Team may request to see the following:

- Both demographic and vaccination data entry workflows, and any alternative workflow methods, including the following:
  - How a patient is added or updated
  - How a next of kin and next of kin’s relationship to the patient is added or updated
  - How an administered vaccine is documented
  - How a historical vaccine is documented
  - How a contraindication is documented
  - How a vaccine refusal is documented

- A comparison between the functionality present in the Site’s EHR and the IIS for the following functionalities:
  - Forecasting recommended vaccinations for patients
  - Contacting patients that are due recommended vaccinations
  - Managing vaccine inventory

2.3. The Site and IIS Team ensure that all remaining questions or concerns documented in the IIS HL7 Site Profile are researched and documented.

3. DEVELOPMENT/INITIAL TESTING – Initial interface configuration is completed on both the IIS side and the Site side based on information gathered during the Planning stage, and is modified as needed until the Go Live stage. Exact steps during the Development stage may vary depending on what was found during previous stages. HL7 messages are tested for adherence and compliance with HL7 Implementation Guide.

3.1. The IIS Team provides the Site ID to the Site Contact, which is needed to ensure the proper mapping of the messages in the IIS.

3.2. EHR vendor successfully installs interface in Site’s local environment(s) (may not be applicable for all EHR vendors). The Site modifies the interface, business processes, and/or staff training.

3.3. The EHR Vendor offers support as changes are made. The scope of changes involving the EHR Vendor can affect the project timeline. (For example: if the Site’s current EHR version is not able to collect data as documented in the implementation guide, the Site might need to upgrade to a version that does collect the required data elements.)

3.4. All parties ensure that all known interface deficits, concerns, and issues are resolved.

3.5. Connectivity testing ensures the interface’s ability to securely send HL7 messages to the IIS.

- The Site staff or the EHR Vendor should inform the IIS Team if the EHR can create but cannot securely send HL7 messages so the IIS Team can provide tools to assist.

3.6. Messages are tested for adherence to HL7 standards.

- EHR vendor or provider organization generates HL7 test message from provider organization's local environment and sends to IIS for formatting review. This step can be done with fake data and will only test the structural validity of the HL7 message and ensure the required elements are present. The provider organization/EHR will need to repeat this step until deemed successful by the IIS team.

4. DATA VALIDATION – Real patient data is submitted from the Site’s Production EHR to the IIS Test environment and reviewed by the IIS Team to ensure quality standards are being met.

4.1. Data validation testing reviews messages for completeness and accuracy, and may reveal previously unknown interface, EHR, workflow, data entry, or other issues needing additional attention. The data quality assurance testing process will appear as follows:

- The Site generates HL7 messages using real patient data and sends to the IIS over the established interface connection.
- IIS staff analyzes the information sent across the interface connection and provides the Site and/or EHR vendor with results.

4.2. The IIS Team reviews the accumulated messages and provides feedback to the Site regarding data quality. The IIS Team will ensure that
the interface meets all IIS requirements in accordance with the IIS HL7 V251 Specification Guide. The Site may share the feedback with their EHR Vendor at their discretion.

- Feedback to the Site will be in the form of aggregate reports and/or patient record-specific reports. The IIS Team may hold a call with the Site contact to discuss how to interpret the report and to discuss projected steps the Site must take to correct errors identified and to improve data quality.

- In some cases, the IIS team will ask the Site to pull specific requested hard-copy patient records and submit to IIS for comparison and data validation.

- In some cases, the IIS team will ask site to compare specific records in the IIS to the EHR to determine source of issues. Provider organization works with IIS staff to resolve issues.

- The IIS may require records be submitted over a certain period of time or that a certain number of records be submitted.

- The IIS may also require that submissions reach a certain threshold for completeness and accuracy before the Site is allowed to go live.

- This process may need to be repeated for several cycles until quality data is achieved.

5. GO LIVE – Final preparations are completed prior to the interface going live and submitting real-time data to the IIS Production system.

5.1. The IIS Team provides IIS-related training to the Site staff. This training includes:

- Any general IIS training required to meet the needs of the Site.

- Specialized training related to HL7 messaging, the interface, etc., including but not limited to Correct Lot Decrementing training.

5.2. The IIS Team will ensure that the Site Contact has all contact information needed to address any issues or concerns as they arise post-go live.

5.3. If the Site is using the IIS to manage their vaccine inventory, the Site’s inventory in the IIS will be reconciled by the Site staff.

- This includes all Sites receiving state supplied vaccines, but can also include those using only private vaccine stock if the Site uses the IIS to manage their private vaccine inventory.

5.4. Any deficiencies in the interface and any resulting required interventions or additional responsibilities of the Site are discussed and agreed upon by the IIS Team and the Site.

- This includes special arrangements based upon unique functions or limitations of the Site’s EHR. For example: if a vaccine is deleted from the Site’s EHR and the interface cannot send an HL7 message that designates the vaccine as such, the Site would be required to manually delete the corresponding information from the IIS to ensure quality patient care.

- These agreements vary greatly depending on the Site’s EHR and other factors.

5.6. Settings and configurations are checked and any changes needed are completed.

5.7. The process is monitored closely by all parties for a period of time determined by the IIS (usually 2-8 weeks).

- IIS staff verify the receipt of enhanced data files submitted to the IIS on go live date.

- Provider organization sends ongoing data files to the IIS.

- Provider organization and/or EHR technical contact monitor and promptly correct any and all errors represented in the HL7 management logs.

Note on working with EHR vendors: In some cases, the IIS may have already worked with specific EHR vendors whose products are used by provider organizations in the IIS’ jurisdiction. Initial testing with the EHR vendors can help in making sure their products can meet the HL7 formatting requirement. If so, testing still should occur at each provider organization with real patient data sent from the provider’s own local EHR environment.
Appendix C-3: Sample Go Live Checklist³³

For (Insert Clinic’s Name) _____________________________________

Below are steps we need to discuss prior to going live. Please review the list and provide me with the relevant information:

1. Proposed go live date: ________________________________

2. Please provide the name and contact info of the person for failed messages and when web service is unavailable. Establish process/resending contingencies.

3. Please provide the name and contact info of the individual (or individuals) who will be responsible for ensuring data quality, reviewing the response files, fixing issues identified in the response files including training staff if necessary. We require both a technical contact and an onsite contact at the provider organization. The provider organization will need to put together a process for how they will monitor inventory issues. How this is done is up to the facility but it is very important that someone review the response files daily to resolve the issues. A plan must be sent for IDPH’s review and approval before the provider organization can go live.

   Technical Contact (Name, email address, phone number):
   __________________________________________________________
   __________________________________________________________

   Onsite Contact (Name, email address, phone number):
   __________________________________________________________
   __________________________________________________________

4. What is the time frame in which error messages from the IIS response files will be resolved?

5. Does your EMR have the ability to re-send updated messages to the IIS? If no, users must re-enter the correct information in both the EMR and in the IIS.

6. Does your EMR have the ability to send deletion messages to IRIS? If no, if a user deletes an immunization in their EMR, they need to log in to the IIS and delete the immunization there as well.

7. Is the lot number typed for each immunization given or is there a dropdown list where the lot number is selected? When lot numbers are mistyped in the EMR, IRIS will not deduct inventory.

8. Confirm provider organization will be using the same certificates in the production environment. If needed, you can submit a new CSR for your production server.

9. Establish a process to communicate or provide training for the staff if needed to correct issues with data entries.

10. Communicate go live date to staff and when they can stop manually updating patient info in IRIS.

11. HP will provide the production URL and password prior to go live.

12. Eve of go live date: Validate inventory is still accurate in IRIS.

Ensure that the person(s) listed have access to IIS.

Some provider organizations can get a consolidated report created by their vendor so that they can easily view the data in the response files instead of reviewing every response file for each job via the user interface.

³³ This sample document is adapted from the Iowa Go Live Checklist, Iowa Department of Public Health, Bureau of Immunization and TB. Provided by Kim Tichy, IRIS Coordinator, June 2, 2016.
Appendix D-1: Selected Data Checks table from MIROW Data Quality Guide

Below is a list of data checks that can be included in the precertification process. Some checks can be done at all levels of data processing (precertification, ongoing, and periodic). Others are more appropriate for precertification because they require more effort. Some checks are more appropriate as database checks because they examine the whole record of a patient, i.e., different submissions have to all merge together and the record is examined as a whole (e.g., x number of immunizations prior to 6 months of age).

<table>
<thead>
<tr>
<th>DATA CHECKS</th>
<th>TYPE OF CHECK</th>
<th>BR#</th>
<th>WHEN</th>
</tr>
</thead>
<tbody>
<tr>
<td>Minimum data set is present</td>
<td>Within record check</td>
<td>BR105, BR106</td>
<td>Pre-, and ongoing</td>
</tr>
<tr>
<td>DOB &lt;= encounter date</td>
<td>Within record check</td>
<td>BR101</td>
<td>Pre-, and ongoing</td>
</tr>
<tr>
<td>All vax except HepB should be &gt; DOB+28 days</td>
<td>Within record check</td>
<td>BR114</td>
<td>Pre-, and ongoing</td>
</tr>
<tr>
<td>Vax name consistent with CPT or CVX code</td>
<td>Within record check</td>
<td>BR116</td>
<td>Pre-, and ongoing</td>
</tr>
<tr>
<td>Historical indicator/vax type contradiction (e.g., NOS with &quot;administered&quot; indicator)</td>
<td>Within record check</td>
<td>BR121</td>
<td>Precertification</td>
</tr>
<tr>
<td>Vax type consistent with route and site</td>
<td>Within record check</td>
<td>BR119</td>
<td>Precertification</td>
</tr>
<tr>
<td>Encounter date &lt; lot expiration date</td>
<td>Within record check</td>
<td>BR118</td>
<td>Pre-, and ongoing</td>
</tr>
<tr>
<td>Encounter date within license date of product</td>
<td>Within record check</td>
<td>BR120</td>
<td>Pre-, and ongoing</td>
</tr>
<tr>
<td>MMR &lt; 361 days</td>
<td>Within record check/ ACIP</td>
<td>BR130</td>
<td>Pre- and periodic</td>
</tr>
<tr>
<td>Varicella &lt; 361 days</td>
<td>Within record check/ ACIP</td>
<td>BR130</td>
<td>Pre- and periodic</td>
</tr>
<tr>
<td>PCV &lt; 6 weeks</td>
<td>Within record check/ ACIP</td>
<td>BR130</td>
<td>Pre- and periodic</td>
</tr>
<tr>
<td>Hib &lt; 6 weeks</td>
<td>Within record check/ ACIP</td>
<td>BR130</td>
<td>Pre- and periodic</td>
</tr>
<tr>
<td>Td to child &lt;7 years of age</td>
<td>Within record check/ ACIP</td>
<td>BR130</td>
<td>Pre- and periodic</td>
</tr>
<tr>
<td>DT, DTaP to child &gt;7 years of age</td>
<td>Within record check/ ACIP</td>
<td>BR130</td>
<td>Pre- and periodic</td>
</tr>
<tr>
<td>Hib-containing vax to child &gt;5 years of age</td>
<td>Within record check/ ACIP</td>
<td>BR130</td>
<td>Pre- and periodic</td>
</tr>
<tr>
<td>PCV to child &gt;5 years of age</td>
<td>Within record check/ ACIP</td>
<td>BR130</td>
<td>Pre- and periodic</td>
</tr>
<tr>
<td>PPV23 to child &lt;2 years of age</td>
<td>Within record check/ ACIP</td>
<td>BR130</td>
<td>Pre- and periodic</td>
</tr>
<tr>
<td>All vaccines are the same</td>
<td>File level checks</td>
<td></td>
<td>Pre-, and ongoing</td>
</tr>
<tr>
<td>All DOBs are the same</td>
<td>File level checks</td>
<td></td>
<td>Pre-, and ongoing</td>
</tr>
<tr>
<td>All vaccine dates are the same</td>
<td>File level checks</td>
<td></td>
<td>Pre-, and ongoing</td>
</tr>
</tbody>
</table>

³⁴ 2008 MIROW Data Quality guide, Table 6, pp 61-62.
## Appendix D-2: Provider Organization Profile Information

Note: References to Appendices E and F in content below refer to those found in the 2008 MIROW Data Quality guide.

### Vaccine distribution based on provider organization profile

This is one of the most important checks that occur in precertification. Each provider organization practice, depending on the age and type of population served, is expected to administer a certain range of vaccine types, and in specific proportions. For each practice type, the IIS can maintain such a profile, and compare incoming data files for conformity to that profile.

This method can identify systemic problems such as:
- miscoding issues (crosswalk errors)
- missing vaccine codes – usually those that have been recently introduced
- systematic data entry error (e.g., entering a pneumococcal polysaccharide instead of a conjugate vaccine)

This method can also identify unusual but accurate patterns that are due to temporary shortages, a shift in the provider organization population, or unusual clinical practice. The most useful types of provider organization profiles are for pediatric practices, or clinics that see all age groups. Profiles can be developed in different ways. Here are some suggestions:

1. Statistically develop provider organization profiles by averaging data in the IIS from all provider organizations of the same type, and compare a specific provider organization’s vaccine distribution to that of the average distribution for that type of provider organization. Large deviations from the average profile may indicate problems, particularly errors or omissions in vaccine codes. See detailed explanation in Appendix F.

2. Develop distributions based on the “ideal” vaccination pattern, i.e., if the population in question receives all recommended immunizations, and compare each provider organization’s pattern to that “ideal” distribution. See Appendix E for examples of such distributions.

3. Establish a provider organization-specific vaccine distribution profile. In this approach, each provider organization would have its own distribution, which would be developed with IIS staff. It would involve

<table>
<thead>
<tr>
<th>DATA CHECKS</th>
<th>TYPE OF CHECK</th>
<th>BR#</th>
<th>WHEN</th>
</tr>
</thead>
<tbody>
<tr>
<td>All names, etc. are the same</td>
<td>File level checks</td>
<td>BR124</td>
<td>Pre-, and ongoing</td>
</tr>
<tr>
<td>Same antigen containing vaccine given more than once on the same day to the same patient</td>
<td>File level checks</td>
<td>BR117</td>
<td>Pre-, and ongoing</td>
</tr>
<tr>
<td>Compare to ideal distribution for type of practice</td>
<td>File level checks</td>
<td>BR113</td>
<td>Pre- and periodic</td>
</tr>
<tr>
<td>More than 50 vax for child &lt;5 years</td>
<td>Database / ACIP</td>
<td>BR128</td>
<td>Periodic</td>
</tr>
<tr>
<td>More than 35 vax for child &lt; 2 years</td>
<td>Database / ACIP</td>
<td>BR128</td>
<td>Periodic</td>
</tr>
<tr>
<td>More than 70 vax lifetime</td>
<td>Database / ACIP</td>
<td>BR128</td>
<td>Periodic</td>
</tr>
<tr>
<td>More than 3 doses Hib/PCV7/DTaP at 6 months</td>
<td>Database / ACIP</td>
<td>BR129</td>
<td>Periodic</td>
</tr>
<tr>
<td>Minimum interval violations</td>
<td>Database / ACIP</td>
<td>BR131</td>
<td>Periodic</td>
</tr>
<tr>
<td>Additional ACIP type rules</td>
<td>Database / ACIP</td>
<td>BR129</td>
<td>Periodic</td>
</tr>
</tbody>
</table>

Note: The above vaccine schedule related examples are subject to change based on ACIP recommendations, and therefore need to be periodically reviewed.

\(^{35}\) 2008 MIROW Data Quality guide, pp 59-60.
working with each and every provider organization to understand and quantify their clinical practice and establish a provider organization-specific profile. Every data file would be compared to that distribution to ensure that no deviations are observed.

The IIS can choose one or more of these methods to establish provider organization profiles depending on resources available. Method 2 is somewhat “quick and dirty” because it establishes the profile based on the recommendation schedule, which is not necessarily what the actual practice may be. However, it is the easiest method, and for all practical purposes it will identify most systematic level errors in incoming data.

Appendix D-3: Provider Organization Profiles – BR113 from 2013 MIROW Data Quality Guide

Table 3. Provider Organization Profile Business Rule

<table>
<thead>
<tr>
<th>BR #</th>
<th>Condition</th>
<th>Recommended Action</th>
<th>Comments</th>
</tr>
</thead>
</table>
| BR113 | If the IIS-AO (Vaccinator) is a “specific,” (e.g., pediatric) practice, the currently administered vaccinations should match a pattern in similar practices  
Note: This could apply to many practices. A practice includes a unique combination of various groups of the population.  
Data items:  
• Vaccine Type  
• Date of Birth  
• Vaccination Encounter Date  
• IIS-AO Type/Sub-Type  
• Administered/Historical Indicator | Accept and flag for investigation (initiate research of provider organization’s records) | See section “Precertification and Providers’ Profiles” and Appendices E and F in 2008 MIROW Guide for specific distributions for various practices and for possible approaches to utilize provider organizations’ profiles  
• Possible approaches may include:  
1. Dialogue with IIS-AO (Vaccinator) to determine if the reported percentages reflect actual clinical activity (e.g., inventory shortage or manual coding errors)  
2. Review data exchange logs for error messages (application errors, system outages) on IIS side and IIS-AO side  
3. Funding and staffing restrictions should be taken under consideration. NYC experience of communicating with IIS-AO regarding their profiles should be considered  
• Principle(s): P01, P05, P06 |

---

56 2013 MIROW Data Quality guide, p 77.
## Appendix D-4: Minimum/Mandatory Dataset from BR 105, 2013 MIROW Guide

Table 4. MIROW BR 105 Details

<table>
<thead>
<tr>
<th>Condition</th>
<th>Recommended Action</th>
<th>Comments</th>
</tr>
</thead>
</table>
| The minimum/mandatory set of data items for the "administered" Vaccination Event submission must include:  
  - IIS-AO ID (Vaccinator/Recorder)  
  - Patient Name, First  
  - Patient Name, Last  
  - Patient Date of Birth  
  - Vaccination Encounter Date  
  - Vaccine Type  
  - Administered/Historical Indicator = "Administered"  
  - Lot Number | When less than minimum/mandatory set is received, the whole submission should always be rejected |  
  - For a recommended (not minimum) set of data items, refer to the list of core data elements [2.1], HL7 standard (IG Implementation Guide) [2.5], local manuals, and other materials.  
  - See the section “Administered/Historical Indicator” in chapter 3 for a discussion (page 27).  
  1. Rules for accepting or rejecting "Administered" Vaccination Event Submissions with less than the expanded data set should be the same for Electronic Data Exchange and Direct User Interface submissions. Note: Typically, when a provider organization first adopts an electronic health record “administered” vaccines from the past do not have lot number data entered into them. For on-boarding purposes a distinction may need to be made between newly administered vaccines and legacy doses of administered vaccines since there are different data quality expectations.  
  2. When a reduced set of data items is reported for the "Administered" Vaccination Event, an error message should always be sent or displayed in the UI. Also, other methods of communicating data quality problems should be employed, i.e., monthly reports.  
  - Vaccine Type can be expressed as a CVX code (preferably) or can be derived from NDC code. (Truncated – see original MIROW document for complete information.) |

BR105R2
The minimum/mandatory set of data items for the “historical” Vaccination Event submission must include:  
  - Patient Name, First  
  - Patient Name, Last  
  - Patient Date of Birth  
  - Vaccination Encounter Date  
  - Vaccine Type  
  - Administered/Historical Indicator = “Historical”

---

Appendix E - Core Data Elements

This appendix lists each of the core data elements that an IIS will be required to store and/or produce per CDC Functional Requirement 3.4 within the 2013-2017 timeframe. This is not a comprehensive list of all items that external information systems such as EHRs, vital records, practice management, or billing systems are expected to store and send; that will likely be included in a future work effort. Where appropriate, the IIS may infer or auto populate distinct values; actual architectural solutions will differ among systems.³⁸

<table>
<thead>
<tr>
<th>Patient ID</th>
<th>Patient Primary Language</th>
</tr>
</thead>
<tbody>
<tr>
<td>Patient Name: First</td>
<td>Patient Telephone Number</td>
</tr>
<tr>
<td>Patient Name: Middle</td>
<td>Patient Telephone Type (e.g., home, cell)</td>
</tr>
<tr>
<td>Patient Name: Last</td>
<td>Patient E-mail address</td>
</tr>
<tr>
<td>Patient Alias Name: First</td>
<td>Patient Status Indicator – Provider facility level</td>
</tr>
<tr>
<td>Patient Alias Name: Middle</td>
<td>Patient Status Indicator – IIS level</td>
</tr>
<tr>
<td>Patient Alias Name: Last</td>
<td>Vaccine Product Type Administered</td>
</tr>
<tr>
<td>Patient Date of Birth</td>
<td>Vaccination Administration Date</td>
</tr>
<tr>
<td>Patient Gender</td>
<td>Vaccine Manufacture Name</td>
</tr>
<tr>
<td>Patient Multiple Birth Indicator</td>
<td>Vaccine Lot Number</td>
</tr>
<tr>
<td>Patient Birth Order</td>
<td>Vaccine Expiration Date</td>
</tr>
<tr>
<td>Responsible Person Name: First</td>
<td>Vaccine Dose Volume and Unit</td>
</tr>
<tr>
<td>Responsible Person Name: Middle</td>
<td>Vaccine Site of Administration</td>
</tr>
<tr>
<td>Responsible Person Name: Last</td>
<td>Vaccine Route of Administration</td>
</tr>
<tr>
<td>Responsible Person Name: Relationship to Patient</td>
<td>Vaccine Ordering Provider Name</td>
</tr>
<tr>
<td>Mother’s Name: First</td>
<td>Vaccine Administering Provider Name</td>
</tr>
<tr>
<td>Mother’s Name: Middle</td>
<td>Vaccine Administering Provider Suffix (e.g., MD, RN, LPN)</td>
</tr>
<tr>
<td>Mother’s Name: Last</td>
<td>Vaccine Event Information Source (administered or historical)</td>
</tr>
<tr>
<td>Mother’s Name: Maiden Last</td>
<td>VFC/grantee program vaccine eligibility at dose level</td>
</tr>
<tr>
<td>Patient Address: Street</td>
<td>VIS Type and Publication Date</td>
</tr>
<tr>
<td>Patient Address: City</td>
<td>VIS Date given to patient</td>
</tr>
<tr>
<td>Patient Address: State</td>
<td>Contraindication(s)/Precaution(s)</td>
</tr>
<tr>
<td>Patient Address: Country</td>
<td>Contraindication(s)/Precaution(s) Observation Date(s)</td>
</tr>
<tr>
<td>Patient Address: Zip code</td>
<td>Exemption(s)/Parent Refusal of Vaccine</td>
</tr>
<tr>
<td>Patient Address: County of Residence</td>
<td>Date of Exemption/Parent Refusal of Vaccine</td>
</tr>
<tr>
<td>Race</td>
<td>Vaccine Reaction(s)</td>
</tr>
<tr>
<td>Ethnicity</td>
<td>History of vaccine preventable disease (e.g., varicella)</td>
</tr>
<tr>
<td>Birthing Facility Name</td>
<td>Date of History of Vaccine Preventable Disease</td>
</tr>
<tr>
<td>Patient Birth State</td>
<td></td>
</tr>
</tbody>
</table>

Appendix F-1. Reports from Massachusetts IIS

Figure 2. Data Quality Input Screen (from Massachusetts IIS)
### Figure 3. Data Quality Output – Overview Report (from Massachusetts IIS)

**Massachusetts Immunization Information System**

**Data Quality Overview**

<table>
<thead>
<tr>
<th>Description</th>
<th>Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total HL7 Messages</td>
<td>147</td>
</tr>
<tr>
<td>Number of Administered Immunizations given to patients &gt;= 19</td>
<td>25</td>
</tr>
<tr>
<td>Number of Historical Immunizations given to patients &gt;= 19</td>
<td>53</td>
</tr>
<tr>
<td>Number of Administered Immunizations given to patients &lt; 19</td>
<td>29</td>
</tr>
<tr>
<td>Number of Historical Immunizations given to patients &lt; 19</td>
<td>40</td>
</tr>
<tr>
<td>Total Immunizations</td>
<td>147</td>
</tr>
<tr>
<td>Percentage of Administered Immunizations given to Patients &lt; 19 with VFC eligibility at the Shot Level</td>
<td>100%</td>
</tr>
<tr>
<td>Percentage of Administered Immunizations with lot number</td>
<td>99%</td>
</tr>
<tr>
<td>Percentage of Administered Immunizations with vaccine manufacturer</td>
<td>100%</td>
</tr>
<tr>
<td>Percentage of Administered Immunizations with Route of Administration</td>
<td>98%</td>
</tr>
<tr>
<td>Percentage of Administered Immunizations with Site of Administration</td>
<td>74%</td>
</tr>
<tr>
<td>Percentage of Administered Immunizations with Missing Units or Units Not Equal to ML</td>
<td>0%</td>
</tr>
<tr>
<td>Percentage of Administered Immunizations missing dose size</td>
<td>6%</td>
</tr>
<tr>
<td>Total # of Administered Immunizations for each CVX code</td>
<td></td>
</tr>
<tr>
<td>DTaP, 5 pertussis antigens (108)</td>
<td>7 (13%)</td>
</tr>
<tr>
<td>DTaP-Hib-IPV (120)</td>
<td>1 (1.9%)</td>
</tr>
<tr>
<td>Flu-IVI(VTV), p-free (140)</td>
<td>3 (5.9%)</td>
</tr>
<tr>
<td>HepA-Adult (52)</td>
<td>2 (3.7%)</td>
</tr>
<tr>
<td>HepA-Peds 2 Dose (83)</td>
<td>5 (9.3%)</td>
</tr>
<tr>
<td>HepB Adult (43)</td>
<td>0 (0.0%)</td>
</tr>
<tr>
<td>Hb-BOP (46)</td>
<td>5 (9.3%)</td>
</tr>
<tr>
<td>Hb-PRP-T (48)</td>
<td>3 (5.9%)</td>
</tr>
<tr>
<td>HPV4 (83)</td>
<td>2 (3.7%)</td>
</tr>
<tr>
<td>HPV9 (150)</td>
<td>4 (7.4%)</td>
</tr>
<tr>
<td>Invalid CVX Code</td>
<td>2 (3.7%)</td>
</tr>
<tr>
<td>IPV (10)</td>
<td>5 (9.3%)</td>
</tr>
<tr>
<td>MCV4-D (Monarcha) (114)</td>
<td>0 (0.0%)</td>
</tr>
<tr>
<td>MMR (3)</td>
<td>4 (7.4%)</td>
</tr>
<tr>
<td>PCV13 (133)</td>
<td>10 (16.7%)</td>
</tr>
<tr>
<td>PPSV23 (33)</td>
<td>11 (20.4%)</td>
</tr>
<tr>
<td>Rotavirus, pentavatient (116)</td>
<td>4 (7.4%)</td>
</tr>
<tr>
<td>Td (9)</td>
<td>1 (1.9%)</td>
</tr>
<tr>
<td>Td-preservative free (113)</td>
<td>5 (9.3%)</td>
</tr>
<tr>
<td>Tdap (115)</td>
<td>40 (74.1%)</td>
</tr>
<tr>
<td>Varicella (21)</td>
<td>4 (7.4%)</td>
</tr>
<tr>
<td>Zoster (Shingles) (121)</td>
<td>2 (3.7%)</td>
</tr>
</tbody>
</table>

This report was printed by Alice Steck at DPH-Immunization Program from the MIIS on May 05, 2016 at 01:50 PM.
Appendix F-2. Reports from Wisconsin IIS\(^4^0\)

**Figure 4.** Report Card – Completeness of Demographic Data (from Wisconsin IIS)

![Data Completeness (Patients)](image)

---

\(^4^0\) Petit, A. Wisconsin Immunization Registry Report Cards: IIS Data Quality Feedback to Providers.
**Figure 5.** Report Card – Completeness of Immunization Data (from Wisconsin IIS)

<table>
<thead>
<tr>
<th>Data Field</th>
<th>Count</th>
<th>Percentage</th>
</tr>
</thead>
<tbody>
<tr>
<td>Vaccine Product Type Administered</td>
<td>181</td>
<td>100.00%</td>
</tr>
<tr>
<td>Vaccine Administration Date</td>
<td>181</td>
<td>100.00%</td>
</tr>
<tr>
<td>Vaccine Manufacturer Name</td>
<td>174</td>
<td>96.13%</td>
</tr>
<tr>
<td>Vaccine Trade Name</td>
<td>174</td>
<td>96.13%</td>
</tr>
<tr>
<td>Vaccine Lot Number</td>
<td>174</td>
<td>96.13%</td>
</tr>
<tr>
<td>Vaccine Expiration Date *</td>
<td>174</td>
<td>96.13%</td>
</tr>
<tr>
<td>Vaccine Dosage</td>
<td>174</td>
<td>96.13%</td>
</tr>
<tr>
<td>Vaccine Site of Administration</td>
<td>154</td>
<td>85.08%</td>
</tr>
<tr>
<td>Vaccine Route of Administration</td>
<td>170</td>
<td>93.92%</td>
</tr>
<tr>
<td>Vaccine Ordering Provider Name</td>
<td>174</td>
<td>96.13%</td>
</tr>
<tr>
<td>Vaccine Administering Provider Name</td>
<td>170</td>
<td>93.92%</td>
</tr>
<tr>
<td>Vaccine Administering Provider Title/Suffix</td>
<td>167</td>
<td>92.27%</td>
</tr>
<tr>
<td>Dose Level Eligibility</td>
<td>174</td>
<td>96.13%</td>
</tr>
</tbody>
</table>

* Only immunizations entered using the WIR Inventory Module retain this data.

**Figure 6.** Report Card – Invalid, Discontinued, and Unexpected Vaccine Dose (from Wisconsin IIS)

<table>
<thead>
<tr>
<th>Discontinued Vaccines</th>
</tr>
</thead>
<tbody>
<tr>
<td>Vaccine</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Invalid Doses</th>
</tr>
</thead>
<tbody>
<tr>
<td>Vaccine Group</td>
</tr>
<tr>
<td>---------------</td>
</tr>
<tr>
<td>HepB</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Unexpected Doses</th>
</tr>
</thead>
<tbody>
<tr>
<td>Case</td>
</tr>
</tbody>
</table>

Indicates specific immunization cases which may be valid, but should not occur frequently.
Figure 7. Report Card – VFC Related Data Quality (from Wisconsin IIS)

![VFC Report Card](image)

Figure 8. Report Card – Recommendations based on Provider Organization's Performance (from Wisconsin IIS)

![Recommendations Table](image)

Figure 8 Note: The percentage column reflects the provider organization's performance for the specific fields. The goal column reflects the IIS goal. Report Card – Invalid, Discontinued, and Unexpected Vaccine Dose (from Wisconsin IIS).
Appendix F-3. Reports from Colorado IIS

CO CIIS Data Validation Finding Reports

A sample size of 40 patients (minimum) are randomly selected from the provider organization’s test file. Patient IDs are given to the provider organization or site which then sends the chart records back to the IIS for comparison to what the IIS received.

“The data validation findings report records the discrepancies that were discovered during the data validation review. The comparison is used to calculate an accuracy rate which is based on the number of discrepancies relative to the total number of reported data on the patient records. Hospitals/Clinics must achieve at least a 95% accuracy rate before they can go live with CIIS.”

A summary report produces the total number of discrepancies, broken down into categories as seen in the first report below. A detailed report displays discrepancy categories, issue descriptions, specific examples, issue details, and corrective actions.

41 Colorado Department of Public Health and Environment, CIIS Data Validation Procedure Manual.
Figure 9. CIIS Data Validation Findings Report (from Colorado IIS)

<table>
<thead>
<tr>
<th>Discrepancy Found</th>
<th>NUMBER FOUND</th>
</tr>
</thead>
<tbody>
<tr>
<td>Incorrect CVX Code</td>
<td></td>
</tr>
<tr>
<td>Missing Parent/Guardian Name</td>
<td></td>
</tr>
</tbody>
</table>

Data Validation RATING: B (87%)

Next Steps

<table>
<thead>
<tr>
<th>If Rating is:</th>
<th>Action</th>
</tr>
</thead>
<tbody>
<tr>
<td>A (95%)</td>
<td>CIIS is ready to take your site live</td>
</tr>
<tr>
<td>B</td>
<td>Please complete the following:</td>
</tr>
<tr>
<td></td>
<td>- Review report and specific issues of concern</td>
</tr>
<tr>
<td></td>
<td>- Review this information with EHR vendor if needed</td>
</tr>
<tr>
<td></td>
<td>- Please resolve issues and apply corrections to EHR and interface (consult EHR vendor if needed)</td>
</tr>
<tr>
<td></td>
<td>- Please provide staff training if needed</td>
</tr>
<tr>
<td></td>
<td>- Please complete 'Reasons/Resolution' field for each example</td>
</tr>
<tr>
<td></td>
<td>- Return Report to CIIS</td>
</tr>
<tr>
<td></td>
<td>- CIIS will complete Data Quality Review to verify corrections</td>
</tr>
<tr>
<td></td>
<td>- Once corrections are verified site will Go Live</td>
</tr>
<tr>
<td>C</td>
<td>Please complete the following:</td>
</tr>
<tr>
<td></td>
<td>- Complete steps above</td>
</tr>
<tr>
<td></td>
<td>- A second Data Validation Review will be performed</td>
</tr>
</tbody>
</table>
**Figure 10. CIIS Data Validation Findings Report – Summary (from Colorado IIS)**

**CIIS Data Validation Findings**

**Summary Page:**

**DATA REVIEWED:** The following data elements were reviewed to check the accuracy and completeness of what is coming across in the interface compared to what is entered into their EHR. Immunization records are checked for appropriate usage of vaccine based on vaccine manufacturer guidelines for licensure dates and the age of the patient at the time of the vaccination. The coding of each immunization is also checked to ensure that it makes sense from a clinical perspective.

<table>
<thead>
<tr>
<th>Data Elements Requested and Reviewed</th>
<th>Passed for Accuracy and Completeness</th>
</tr>
</thead>
<tbody>
<tr>
<td>Patient’s first and last name</td>
<td>✓</td>
</tr>
<tr>
<td>Patient’s Gender</td>
<td>✓</td>
</tr>
<tr>
<td>Patient’s DOB</td>
<td>✓</td>
</tr>
<tr>
<td>Patient’s Address</td>
<td>✓</td>
</tr>
<tr>
<td>Patient’s Phone Number</td>
<td>✓</td>
</tr>
<tr>
<td>Parent/Guardian Name</td>
<td>✓</td>
</tr>
<tr>
<td>Vaccination Admin Date</td>
<td>✓</td>
</tr>
<tr>
<td>Vaccine Name</td>
<td>✓</td>
</tr>
<tr>
<td>Vaccine Lot ID #</td>
<td>✓</td>
</tr>
<tr>
<td>Vaccine Dosage (mL)</td>
<td>✓</td>
</tr>
<tr>
<td>Manufacturer/Trade Name</td>
<td>✓</td>
</tr>
<tr>
<td>Administered Route</td>
<td>✓</td>
</tr>
<tr>
<td>Administered Body Site</td>
<td>✓</td>
</tr>
<tr>
<td>Vaccine Expiration Date</td>
<td>✓</td>
</tr>
<tr>
<td>Administered By</td>
<td>✓</td>
</tr>
<tr>
<td>VIS Edition Date</td>
<td>✓</td>
</tr>
<tr>
<td>Date the VIS Sheet was Given</td>
<td>✓</td>
</tr>
<tr>
<td>VFC Eligibility</td>
<td>✓</td>
</tr>
<tr>
<td>Funding Source</td>
<td>✓</td>
</tr>
<tr>
<td>Administering Clinic/Hospital</td>
<td>✓</td>
</tr>
<tr>
<td>CVX/CPT code</td>
<td>✓</td>
</tr>
</tbody>
</table>

**Data Validation Review Summary**

<table>
<thead>
<tr>
<th>What’s Going On:</th>
<th>What’s Seen:</th>
<th>What Needs To Be Done:</th>
<th>See Table:</th>
</tr>
</thead>
<tbody>
<tr>
<td>Incorrect CVX Code</td>
<td>Daptacel : CVX 20</td>
<td>Correct Code:</td>
<td>106</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>1</td>
</tr>
<tr>
<td>Missing parent’s name</td>
<td>Missing in electronic record</td>
<td>Workflow/training</td>
<td>2</td>
</tr>
</tbody>
</table>
Figure 11. Data Validation Findings Report - Patient Specific Review (from Colorado IIS)

Table 1: Incorrect CVX Code

<table>
<thead>
<tr>
<th>Patient Name</th>
<th>Incorrect CVX Code</th>
<th>Actual Code</th>
<th>What Needs to be Done and Questions</th>
<th>Resolution/Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>12345</td>
<td>Dispactol 20 75/516</td>
<td>Dispactol</td>
<td>Verify that the CVX code in the EHR is correct</td>
<td>EHR inventory update with CVX code 108, Yes - No</td>
</tr>
</tbody>
</table>

Table 2: Missing Patient/Guardian Name

<table>
<thead>
<tr>
<th>Patient Name</th>
<th>Incorrect CVX Code</th>
<th>Actual Code</th>
<th>What Needs to be Done and Questions</th>
<th>Resolution/Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>67890</td>
<td>Patients younger than 10 years of age are missing the parent/guardian name in the electronic record and from the EHR</td>
<td>Patients younger than 10 years of age are missing the parent/guardian name in the electronic record and from the EHR</td>
<td>Verify if the EHR has the parent/guardian name</td>
<td>EHR has updated parent/guardian name: Yes - No</td>
</tr>
</tbody>
</table>

APPENDIX F: Sample Data Quality Reports

Figures 11 and 12: Data Validation Findings and Resolution Reports (continued)
Appendix F-4. Reports from NYC Citywide Immunization Registry

Figure 12. HL7 QA Stats Report (from New York City IIS)

Appendix F-5. Pre-HL7 Message Review
Process Description – from Missouri

Data Extracts

A data quality assessment will be conducted of the provider organization’s data prior to moving the organization into the message validation stage. The organization submits a CVX code table listing, and also submits 500-1000 patient and immunization records to DHSS in non-HL7 format. This patient/immunization data will consist of two separate spreadsheets (patient data, immunization data for the same patients). This data should be a real representation of what the organization will actually be sending, and the file can be submitted via secure email or dropped into the SFTP site. If the latter, we give them login credentials to the SFTP site.

Examples of what we will be looking for to correct when reviewing the sample data:

- Dates (dates of birth, immunization dates, etc.) are valid; no future dates
- No test data in a file that is supposed to have been production data; example- Joe Test, Test Address, Test State, etc.
- First and Last name in their respective fields, not just the First Name field
- City, State and Zip in their respective fields, not in one address space
- Code identification has been represented correctly, for example (1) if the patient identifier is labeled DCN, the identifier should be a DCN, not an internal organization ID or SSN, or (2) checking for the proper use of codes to represent race and ethnicity in accordance with HL7 standards
- CVX codes are valid

Once the provider fixes any issues they might have with their spreadsheet data their messages can be validated.

---